

# Exosomal PD-L1 contributes to immunosuppression and response

Nature

560, 382-386

DOI: [10.1038/s41586-018-0392-8](https://doi.org/10.1038/s41586-018-0392-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. , 2016, 4, 65.		100
2	Clinical significance of tumor-infiltrating lymphocytes in breast cancer. , 2016, 4, 59.		530
3	PD-L1. Journal of Clinical Pathology, 2018, 71, 189-194.	1.0	218
4	A proteomic analysis of serum-derived exosomes in rheumatoid arthritis. BMC Rheumatology, 2018, 2, 35.	0.6	35
5	Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 5178-5183.	0.6	2
6	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Frontiers in Microbiology, 2018, 9, 3158.	1.5	66
8	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Medicine, 2018, 10, 93.	3.6	121
9	Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy. Vaccines, 2018, 6, 69.	2.1	96
10	Probing the mechanisms of extracellular vesicle biogenesis and function in cancer. Biochemical Society Transactions, 2018, 46, 1137-1146.	1.6	28
11	Aggregation-Induced Emission: A Trailblazing Journey to the Field of Biomedicine. ACS Applied Bio Materials, 2018, 1, 1768-1786.	2.3	219
12	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
13	Long-term Host Immune Response Trajectories Among Hospitalized Patients With Sepsis. JAMA Network Open, 2019, 2, e198686.	2.8	96
14	Extracellular Vesicles: Catching the Light in Zebrafish. Trends in Cell Biology, 2019, 29, 770-776.	3.6	38
15	PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. , 2019, 7, 209.		73
16	Functions of Exosomes in the Triangular Relationship between the Tumor, Inflammation, and Immunity in the Tumor Microenvironment. Journal of Immunology Research, 2019, 2019, 1-10.	0.9	30
17	Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target. Cancers, 2019, 11, 1147.	1.7	54
18	Role of Extracellular Vesicles in Renal Inflammation and Fibrosis. Advances in Experimental Medicine and Biology, 2019, 1165, 455-466.	0.8	3
19	Pseudoprogression: an indicator for cure in combined immunotherapy?. Immunotherapy, 2019, 11, 1087-1093.	1.0	6

#	ARTICLE	IF	CITATIONS
20	Natural melanoma-derived extracellular vesicles. <i>Seminars in Cancer Biology</i> , 2019, 59, 251-265.	4.3	32
21	Extracellular Vesicles in Epstein-Barr Virus Pathogenesis. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 121-131.	1.8	16
22	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998.	1.0	28
23	Rapid Lipid-Based Approach for Normalization of Quantum-Dot-Detected Biomarker Expression on Extracellular Vesicles in Complex Biological Samples. <i>Nano Letters</i> , 2019, 19, 7623-7631.	4.5	37
24	Latest advances in extracellular vesicles: from bench to bedside. <i>Science and Technology of Advanced Materials</i> , 2019, 20, 746-757.	2.8	74
25	Role of exosomes in tumour and transplant immune regulation. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12807.	1.3	21
26	Roles of exosomes in metastatic colorectal cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 317, C869-C880.	2.1	28
27	Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 5033-5046.	1.3	9
28	Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4203-4219.	2.4	51
29	Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. , 2019, 7, 173.		76
30	Tumor-released autophagosomes induces CD4+ T cell-mediated immunosuppression via a TLR2-IL-6 cascade. , 2019, 7, 178.		37
31	Extracellular Vesicles and Their Potential Use in Monitoring Cancer Progression and Therapy: The Contribution of Proteomics. <i>Journal of Oncology</i> , 2019, 2019, 1-19.	0.6	64
32	Integrative Approaches to Cancer Immunotherapy. <i>Trends in Cancer</i> , 2019, 5, 400-410.	3.8	64
33	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. <i>Scientific Reports</i> , 2019, 9, 10677.	1.6	37
34	Focused ultrasound-augmented targeting delivery of nanosensitizers from homogenous exosomes for enhanced sonodynamic cancer therapy. <i>Theranostics</i> , 2019, 9, 5261-5281.	4.6	106
35	Long Non-coding RNA FENDRR Acts as a miR-423-5p Sponge to Suppress the Treg-Mediated Immune Escape of Hepatocellular Carcinoma Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 516-529.	2.3	109
36	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. <i>Cancer Research</i> , 2019, 79, 4715-4728.	0.4	97
37	The biological functions and clinical applications of exosomes in lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4613-4633.	2.4	90

#	ARTICLE	IF	CITATIONS
38	PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 1050.	1.7	50
39	Biohybrid Nanoparticles to Negotiate with Biological Barriers. <i>Small</i> , 2019, 15, e1902333.	5.2	22
40	Potential role of exosomes in cancer therapy. <i>Precision Radiation Oncology</i> , 2019, 3, 59-64.	0.4	8
41	Targeting Exosomal EBV-LMP1 Transfer and miR-203 Expression via the NF- $\kappa$ B Pathway: The Therapeutic Role of Aspirin in NPC. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 175-184.	2.3	33
42	Extracellular vesicles from human urine-derived stem cells prevent osteoporosis by transferring CTHRC1 and OPG. <i>Bone Research</i> , 2019, 7, 18.	5.4	66
43	Extracellular Vesicles: Subcellular Organelles With the Potential to Spread Cancer Resistance. <i>Anticancer Research</i> , 2019, 39, 3395-3404.	0.5	17
44	Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein. <i>Small</i> , 2019, 15, e1902686.	5.2	58
45	New insights into extracellular vesicle biogenesis and function. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	152
46	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3000.	5.8	194
47	Exosomal circRNAs: biogenesis, effect and application in human diseases. <i>Molecular Cancer</i> , 2019, 18, 116.	7.9	424
48	Extracellular Vesicles Enhance Multiple Myeloma Metastatic Dissemination. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3236.	1.8	38
49	Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	52
50	Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer. <i>Cancer Medicine</i> , 2019, 8, 7728-7740.	1.3	74
51	Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. <i>Drug Resistance Updates</i> , 2019, 47, 100647.	6.5	104
52	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , 2019, 11, 1554.	1.7	73
53	Impact of Chemotherapy on Extracellular Vesicles: Understanding the Chemo-EVs. <i>Frontiers in Oncology</i> , 2019, 9, 1113.	1.3	36
54	Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
55	Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 41.	7.1	150

#	ARTICLE	IF	CITATIONS
56	Liquid biopsy tracking of lung tumor evolutions over time. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1099-1108.	1.5	50
57	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. <i>Drug Resistance Updates</i> , 2019, 47, 100646.	6.5	81
58	Mechanisms Controlling PD-L1 Expression in Cancer. <i>Molecular Cell</i> , 2019, 76, 359-370.	4.5	501
59	Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1901779.	5.6	179
60	A novel strategy for facile serum exosome isolation based on specific interactions between phospholipid bilayers and TiO <sub>2</sub> . <i>Chemical Science</i> , 2019, 10, 1579-1588.	3.7	134
61	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	1.8	150
62	Circulating biomarkers of response to immunotherapy in cancer treatment. <i>Pharmacogenomics</i> , 2019, 20, 1247-1249.	0.6	0
63	Exosomes and pancreatic diseases: status, challenges, and hopes. <i>International Journal of Biological Sciences</i> , 2019, 15, 1846-1860.	2.6	22
64	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102812.	2.0	7
65	Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1079-1088.	1.5	15
66	HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 2438-2447.	2.6	28
67	Exosome-Transmitted lncRNA H19 Inhibits the Growth of Pituitary Adenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6345-6356.	1.8	45
68	lncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. <i>Cell Death and Disease</i> , 2019, 10, 829.	2.7	212
69	Extracellular vesicles in urologic malignancies—Implementations for future cancer care. <i>Cell Proliferation</i> , 2019, 52, e12659.	2.4	20
70	Intercellular transfer of HLA-EG: its potential in cancer immunology. <i>Clinical and Translational Immunology</i> , 2019, 8, e1077.	1.7	33
71	Proteomics comparison of exosomes from serum and plasma between ultracentrifugation and polymer-based precipitation kit methods. <i>Electrophoresis</i> , 2019, 40, 3092-3098.	1.3	49
72	Emergent membrane morphologies in relaxed and tense membranes in presence of reversible adhesive pinning interactions. <i>Physical Biology</i> , 2019, 16, 066011.	0.8	10
73	The role of exosomal PD-L1 in tumor progression and immunotherapy. <i>Molecular Cancer</i> , 2019, 18, 146.	7.9	236

#	ARTICLE	IF	CITATIONS
74	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. , 2019, 7, 274.		26
75	Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Seminars in Cancer Biology, 2019, 59, 236-250.	4.3	200
76	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature Reviews Cancer, 2019, 19, 553-567.	12.8	393
77	Multiplex isolation and profiling of extracellular vesicles using a microfluidic DICE device. Analyst, The, 2019, 144, 5785-5793.	1.7	15
78	Differential Effects of Extracellular Vesicles of Lineage-Specific Human Pluripotent Stem Cells on the Cellular Behaviors of Isogenic Cortical Spheroids. Cells, 2019, 8, 993.	1.8	29
79	Engineered nanoparticles circumvent the adaptive treatment tolerance to immune-checkpoint blockade therapy. Science China Chemistry, 2019, 62, 1557-1560.	4.2	5
80	Tâ€cellâ€ derived extracellular vesicles regulate Bâ€cell IgG production<i>via</i>pyruvate kinase muscle isozyme 2. FASEB Journal, 2019, 33, 12780-12799.	0.2	14
81	Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Review of Molecular Diagnostics, 2019, 19, 895-904.	1.5	28
82	Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis. Frontiers in Pharmacology, 2019, 10, 1029.	1.6	39
83	Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. Frontiers in Oncology, 2019, 9, 1015.	1.3	42
84	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Frontiers in Immunology, 2019, 10, 2298.	2.2	244
85	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534.	1.0	41
86	CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nature Communications, 2019, 10, 4355.	5.8	270
87	Classical Hodgkinâ€™s Lymphoma in the Era of Immune Checkpoint Inhibition. Journal of Clinical Medicine, 2019, 8, 1596.	1.0	15
88	Exosomes in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2019, 9, 894.	1.3	42
89	Myeloid-Derived Suppressive Cells Promote B cellâ€Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma. Cancer Immunology Research, 2019, 7, 1928-1943.	1.6	99
90	Deciphering the Molecular Profile of Lung Cancer: New Strategies for the Early Detection and Prognostic Stratification. Journal of Clinical Medicine, 2019, 8, 108.	1.0	6
91	Exploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery. Advanced Healthcare Materials, 2019, 8, e1801268.	3.9	94

#	ARTICLE	IF	CITATIONS
92	The Prognostic and Therapeutic Value of PD-L1 in Glioma. <i>Frontiers in Pharmacology</i> , 2018, 9, 1503.	1.6	85
93	Near-Infrared Afterglow Semiconducting Nano-Polycomplexes for the Multiplex Differentiation of Cancer Exosomes. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 4983-4987.	7.2	170
94	Exosomes and the Future of Immunotherapy in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 567.	1.8	64
95	Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells. <i>Carcinogenesis</i> , 2019, , .	1.3	17
96	PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. <i>Cell Proliferation</i> , 2019, 52, e12571.	2.4	94
97	Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. <i>ACS Nano</i> , 2019, 13, 6670-6688.	7.3	341
98	The ESCRT-machinery: closing holes and expanding roles. <i>Current Opinion in Cell Biology</i> , 2019, 59, 121-132.	2.6	108
99	Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. <i>International Journal of Cancer</i> , 2019, 145, 2521-2534.	2.3	59
100	Exosomes. <i>Annual Review of Biochemistry</i> , 2019, 88, 487-514.	5.0	1,570
101	Extracellular vesicles in type 2 diabetes mellitus: key roles in pathogenesis, complications, and therapy. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1625677.	5.5	88
102	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
103	Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. <i>Cancer Letters</i> , 2019, 460, 42-53.	3.2	70
104	Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 874.	1.7	85
105	Salivary Extracellular Vesicle-Associated exRNA as Cancer Biomarker. <i>Cancers</i> , 2019, 11, 891.	1.7	37
106	HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape. <i>Cells</i> , 2019, 8, 558.	1.8	94
107	Hematological Malignancy-Derived Small Extracellular Vesicles and Tumor Microenvironment: The Art of Turning Foes into Friends. <i>Cells</i> , 2019, 8, 511.	1.8	26
108	Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis. <i>Theranostics</i> , 2019, 9, 2618-2636.	4.6	39
109	Platycodin D triggers the extracellular release of programmed death Ligand-1 in lung cancer cells. <i>Food and Chemical Toxicology</i> , 2019, 131, 110537.	1.8	46

#	ARTICLE	IF	CITATIONS
110	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer, 2019, 19, 558.	1.1	106
111	High-affinity peptide ligand LXY30 for targeting $\alpha 3 \beta 1$ integrin in non-small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 56.	6.9	28
112	Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Letters, 2019, 460, 1-9.	3.2	156
113	&lt;p&gt;TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 4743-4756.	0.9	9
114	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Frontiers in Medicine, 2019, 6, 119.	1.2	145
115	In vitro assessment of PD-L1+ microvesicles in the cyst fluid of non-syndromic odontogenic keratocysts. Journal of Molecular Histology, 2019, 50, 325-333.	1.0	3
116	Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer. Clinica Chimica Acta, 2019, 495, 331-337.	0.5	41
117	The Proteome of Pancreatic Cancerâ€Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways. Proteomics, 2019, 19, e1800394.	1.3	19
118	Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10488-10493.	3.3	54
119	Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine. Cancer Research, 2019, 79, 2798-2804.	0.4	111
120	Translation of cancer immunotherapy from the bench to the bedside. Advances in Cancer Research, 2019, 143, 1-62.	1.9	28
121	Aptamer-based fluorescence polarization assay for separation-free exosome quantification. Nanoscale, 2019, 11, 10106-10113.	2.8	66
122	Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine, 2019, 11, .	5.8	595
123	Advances in Technologies for Purification and Enrichment of Extracellular Vesicles. SLAS Technology, 2019, 24, 477-488.	1.0	29
124	Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis. Annals of Surgical Oncology, 2019, 26, 3745-3755.	0.7	131
125	Roles of exosomes in liver metastases: Novel diagnosis and treatment choices. Journal of Cellular Physiology, 2019, 234, 21588-21600.	2.0	13
126	Recent Advances in Biosensors for Detecting Cancer-Derived Exosomes. Trends in Biotechnology, 2019, 37, 1236-1254.	4.9	155
127	Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives. International Journal of Molecular Sciences, 2019, 20, 2272.	1.8	143



#	ARTICLE	IF	CITATIONS
128	SALL4-mediated upregulation of exosomal miR-146a-5p drives T-cell exhaustion by M2 tumor-associated macrophages in HCC. <i>Oncolmunology</i> , 2019, 8, e1601479.	2.1	108
129	Role of extracellular vesicles in stem cell biology. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 317, C303-C313.	2.1	44
130	Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer. <i>Chemical Science</i> , 2019, 10, 5495-5504.	3.7	118
131	Metastatic Niches and the Modulatory Contribution of Mesenchymal Stem Cells and Its Exosomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1946.	1.8	15
132	Vps4A mediates the localization and exosome release of $\beta$ -catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma. <i>Cancer Letters</i> , 2019, 457, 47-59.	3.2	41
133	Exosome-Mediated Metastasis: Communication from a Distance. <i>Developmental Cell</i> , 2019, 49, 347-360.	3.1	802
134	Immune checkpoint inhibition for the treatment of mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 697-706.	1.4	18
135	Exosomes in cancer development, metastasis, and immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 455-468.	3.3	532
136	Life and death of circulating cell-free DNA. <i>Cancer Biology and Therapy</i> , 2019, 20, 1057-1067.	1.5	327
137	Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis. <i>Cancer Medicine</i> , 2019, 8, 3059-3071.	1.3	9
138	Fully Automated, Label-Free Isolation of Extracellular Vesicles from Whole Blood for Cancer Diagnosis and Monitoring. <i>Theranostics</i> , 2019, 9, 1851-1863.	4.6	74
139	Exosomes: The Indispensable Messenger in Tumor Pathogenesis and the Rising Star in Antitumor Applications. <i>Advanced Biology</i> , 2019, 3, e1900008.	3.0	8
140	Exosomal PD-L1: an effective liquid biopsy target to predict immunotherapy response. <i>National Science Review</i> , 2019, 6, 1103-1104.	4.6	13
141	Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. <i>Molecular Cancer</i> , 2019, 18, 32.	7.9	271
142	Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. <i>Nature Communications</i> , 2019, 10, 1387.	5.8	130
143	Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. <i>Nature Biomedical Engineering</i> , 2019, 3, 306-317.	11.6	279
144	Challenges and opportunities in exosome research—Perspectives from biology, engineering, and cancer therapy. <i>APL Bioengineering</i> , 2019, 3, 011503.	3.3	327
145	Effects of exosomes on pre-metastatic niche formation in tumors. <i>Molecular Cancer</i> , 2019, 18, 39.	7.9	280

#	ARTICLE	IF	CITATIONS
146	Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-“small cell lung cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 982-1000.	4.2	173
147	Exploiting the message from cancer: the diagnostic value of extracellular vesicles for clinical applications. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-9.	3.2	87
148	The role of extracellular vesicles from different origin in the microenvironment of head and neck cancers. <i>Molecular Cancer</i> , 2019, 18, 83.	7.9	85
149	Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy. <i>Current Pharmaceutical Design</i> , 2019, 24, 4911-4920.	0.9	27
150	A Review of Exosomes and their Role in The Tumor Microenvironment and Host-Tumor "Macroenvironment". <i>Journal of Immunological Sciences</i> , 2019, 3, 4-8.	0.5	43
151	Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis. <i>Frontiers in Genetics</i> , 2019, 10, 202.	1.1	59
152	Mechanisms associated with biogenesis of exosomes in cancer. <i>Molecular Cancer</i> , 2019, 18, 52.	7.9	251
153	Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. <i>Molecular Cancer</i> , 2019, 18, 55.	7.9	304
154	Extracellular vesicles in the tumor microenvironment: old stories, but new tales. <i>Molecular Cancer</i> , 2019, 18, 59.	7.9	205
155	Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. <i>Cell</i> , 2019, 177, 414-427.e13.	13.5	847
156	Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF- $\kappa$ B Contributes to UV Radiation-Induced Immune Suppression. <i>Cancer Research</i> , 2019, 79, 2909-2922.	0.4	77
157	Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma. <i>European Respiratory Journal</i> , 2019, 53, 1802444.	3.1	2
158	Role of Exosomes in the Regulation of T-cell Mediated Immune Responses and in Autoimmune Disease. <i>Cells</i> , 2019, 8, 154.	1.8	121
159	Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 636-646.	1.3	24
160	Near-Infrared Afterglow Semiconducting Nano-Polycomplexes for the Multiplex Differentiation of Cancer Exosomes. <i>Angewandte Chemie</i> , 2019, 131, 5037-5041.	1.6	43
161	The role of exosomal shuttle RNA (esRNA) in lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 27-34.	2.0	13
162	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
163	Bridging exosome and liposome through zirconium-phosphate coordination chemistry: a new method for exosome detection. <i>Chemical Communications</i> , 2019, 55, 2708-2711.	2.2	64

#	ARTICLE	IF	CITATIONS
164	Emodin: Its role in prostate cancer-associated inflammation (Review). <i>Oncology Reports</i> , 2019, 42, 1259-1271.	1.2	13
165	ASO Author Reflections: The Prognostic Role of Exosomal PD-L1 in Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 851-852.	0.7	6
166	CD3+CD56+ natural killer T cell infiltration is increased in cervical cancer and negatively correlated with tumour progression. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 1380-1391.	0.5	2
167	Melanoma and Vitiligo: In Good Company. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5731.	1.8	40
168	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
169	Isolation and Detection Technologies of Extracellular Vesicles and Application on Cancer Diagnostic. <i>Dose-Response</i> , 2019, 17, 155932581989100.	0.7	37
170	The Emerging Roles of Extracellular Vesicles in Osteosarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 1342.	1.3	33
171	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. <i>Radiology Imaging Cancer</i> , 2019, 1, e190031.	0.7	22
172	Delivery strategies of cancer immunotherapy: recent advances and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 126.	6.9	96
173	Circulating Exosomal miR-150-5p and miR-99b-5p as Diagnostic Biomarkers for Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1129.	1.3	55
174	From Tumor Metastasis towards Cerebral Ischemia—Extracellular Vesicles as a General Concept of Intercellular Communication Processes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5995.	1.8	4
175	Biomarker for personalized immunotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, S308-S317.	1.3	7
176	Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. <i>Frontiers in Immunology</i> , 2019, 10, 2876.	2.2	60
177	Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. <i>Cancer Cell International</i> , 2019, 19, 341.	1.8	90
178	The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling. <i>Frontiers in Oncology</i> , 2019, 9, 1347.	1.3	19
179	Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma. <i>Journal of Immunotherapy</i> , 2019, 42, 321-330.	1.2	31
180	Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	0.6	32
181	Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. <i>Communications Biology</i> , 2019, 2, 386.	2.0	81

#	ARTICLE	IF	CITATIONS
182	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
183	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1237.	1.3	106
184	CD8+ T <sub>H</sub> 1/2 cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM-CSF and IL-12, enhance the anti-renal cortical adenocarcinoma effect. <i>Oncology Reports</i> , 2019, 42, 866-879.	1.2	22
186	Extracellular Vesicles: New Players in Lymphomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 41.	1.8	26
187	Exosome-Mediated Signaling in Epithelial to Mesenchymal Transition and Tumor Progression. <i>Journal of Clinical Medicine</i> , 2019, 8, 26.	1.0	55
188	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 105-115.	0.9	16
189	RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes. <i>International Journal of Cancer</i> , 2019, 144, 3070-3085.	2.3	72
190	Exosomes: The next generation of endogenous nanomaterials for advanced drug delivery and therapy. <i>Acta Biomaterialia</i> , 2019, 86, 1-14.	4.1	275
191	HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. <i>Nature Chemical Biology</i> , 2019, 15, 42-50.	3.9	189
192	Re: Circulating Extracellular Vesicles in Human Disease. <i>European Urology</i> , 2019, 75, 342-343.	0.9	4
193	Extracellular membrane vesicles in the three domains of life and beyond. <i>FEMS Microbiology Reviews</i> , 2019, 43, 273-303.	3.9	289
194	Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2392-2402.	3.2	282
195	Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. <i>Molecular Cancer</i> , 2019, 18, 10.	7.9	810
196	The role of extracellular vesicles in cancer microenvironment and metastasis: myths and challenges. <i>Biochemical Society Transactions</i> , 2019, 47, 273-280.	1.6	21
197	The critical role of exosomes in tumor biology. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 6820-6832.	1.2	7
198	Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 407-420.	1.4	39
199	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 106, 144-159.	1.3	164
200	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093

#	ARTICLE	IF	CITATIONS
201	Tumour-intrinsic resistance to immune checkpoint blockade. <i>Nature Reviews Immunology</i> , 2020, 20, 25-39.	10.6	856
202	Reprogramming extracellular vesicles with engineered proteins. <i>Methods</i> , 2020, 177, 95-102.	1.9	16
203	Exosome basic mechanisms. , 2020, , 1-21.		6
204	Tumor-derived exosomes (TDEs): How to avoid the sting in the tail. <i>Medicinal Research Reviews</i> , 2020, 40, 385-412.	5.0	35
205	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , 2020, 39, 187-203.	2.6	34
206	Simultaneous Detection of Exosomal Membrane Protein and RNA by Highly Sensitive Aptamer Assisted Multiplexed PCR. <i>ACS Applied Bio Materials</i> , 2020, 3, 2560-2567.	2.3	22
207	Comparative gene expression analysis in melanocytes driven by tumor cell-derived exosomes. <i>Experimental Cell Research</i> , 2020, 386, 111690.	1.2	9
208	Extracellular vesicles as biomarkers and therapeutic targets for cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 318, C29-C39.	2.1	162
209	Exosomes and Nanoengineering: A Match Made for Precision Therapeutics. <i>Advanced Materials</i> , 2020, 32, e1904040.	11.1	134
210	Personalized detection of circling exosomal PD-L1 based on Fe <sub>3</sub> O <sub>4</sub> @TiO <sub>2</sub> isolation and SERS immunoassay. <i>Biosensors and Bioelectronics</i> , 2020, 148, 111800.	5.3	150
211	Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 144-152.	0.6	69
212	Extracellular Vesicles and Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037275.	2.9	31
213	Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 4800-4805.	7.2	159
214	Current issues and perspectives in PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 790-800.	1.0	120
215	Engineering of Exosomes to Target Cancer Metastasis. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 1-16.	1.0	58
216	Large extracellular vesicles: Size matters in tumor progression. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 69-74.	3.2	41
217	Deliver anti-PD-L1 into brain by p-hydroxybenzoic acid to enhance immunotherapeutic effect for glioblastoma. <i>Journal of Controlled Release</i> , 2020, 320, 63-72.	4.8	39
218	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. <i>Scientific Reports</i> , 2020, 10, 92.	1.6	122

#	ARTICLE	IF	CITATIONS
219	The significance of exosomes in the development and treatment of hepatocellular carcinoma. <i>Molecular Cancer</i> , 2020, 19, 1.	7.9	387
220	Exosomal PD-L1 functions as an immunosuppressant to promote wound healing. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1709262.	5.5	67
221	An emerging interplay between extracellular vesicles and cytokines. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 49-60.	3.2	35
222	Advances in biosensing technologies for analysis of cancer-derived exosomes. <i>TrAC - Trends in Analytical Chemistry</i> , 2020, 123, 115773.	5.8	29
223	Purity and yield of melanoma exosomes are dependent on isolation method. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1692401.	5.5	99
224	Fabrication of an Aptamer-Coated Liposome Complex for the Detection and Profiling of Exosomes Based on Terminal Deoxynucleotidyl Transferase-Mediated Signal Amplification. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 322-329.	4.0	63
225	Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. <i>Clinical and Experimental Immunology</i> , 2020, 200, 45-52.	1.1	40
226	Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy. <i>Cancers</i> , 2020, 12, 40.	1.7	20
227	Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression. <i>Cancers</i> , 2020, 12, 57.	1.7	22
228	Host- and Microbiota-Derived Extracellular Vesicles, Immune Function, and Disease Development. <i>International Journal of Molecular Sciences</i> , 2020, 21, 107.	1.8	142
229	The Effects of IL-1 <sup>β</sup> on Astrocytes are Conveyed by Extracellular Vesicles and Influenced by Age. <i>Neurochemical Research</i> , 2020, 45, 694-707.	1.6	8
230	Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. <i>Science Advances</i> , 2020, 6, .	4.7	58
231	Extracellular Vesicles as Biomarkers in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 2825.	1.7	66
232	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	1.1	11
233	Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 242.	7.1	190
234	&lt;p&gt;Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 8019-8036.	3.3	212
235	Exosomal vesicles enhance immunosuppression in chronic inflammation: Impact in cellular senescence and the aging process. <i>Cellular Signalling</i> , 2020, 75, 109771.	1.7	18
236	Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer. <i>Cancer Letters</i> , 2020, 495, 1-11.	3.2	13

#	ARTICLE	IF	CITATIONS
237	Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis. <i>Cancers</i> , 2020, 12, 2893.	1.7	14
238	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
239	Role of extracellular vesicles in tumour microenvironment. <i>Cell Communication and Signaling</i> , 2020, 18, 163.	2.7	43
240	EVs as Potential New Therapeutic Tool/Target in Gastrointestinal Cancer and HCC. <i>Cancers</i> , 2020, 12, 3019.	1.7	18
241	Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients. <i>Journal of Nanobiotechnology</i> , 2020, 18, 151.	4.2	49
242	In vivo imaging of long-term accumulation of cancer-derived exosomes using a BRET-based reporter. <i>Scientific Reports</i> , 2020, 10, 16616.	1.6	17
243	Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 110-123.	6.6	23
244	Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy. <i>Advanced Materials</i> , 2020, 32, e2002440.	11.1	160
245	Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. <i>International Immunopharmacology</i> , 2020, 88, 106971.	1.7	7
246	Emerging role of tumor cell plasticity in modifying therapeutic response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 228.	7.1	120
247	An efficient method to isolate lemon derived extracellular vesicles for gastric cancer therapy. <i>Journal of Nanobiotechnology</i> , 2020, 18, 100.	4.2	98
248	microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 1214.	2.2	12
249	Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. <i>Radiation Oncology</i> , 2020, 15, 167.	1.2	29
250	Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. <i>Cells</i> , 2020, 9, 1645.	1.8	5
251	The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. <i>Cell Communication and Signaling</i> , 2020, 18, 112.	2.7	62
252	Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. <i>Archives of Biochemistry and Biophysics</i> , 2020, 690, 108479.	1.4	30
253	Signaling of Tumor-Derived sEV Impacts Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5066.	1.8	25
254	Applying CRISPR/Cas13 to Construct Exosomal PD-L1 Ultrasensitive Biosensors for Dynamic Monitoring of Tumor Progression in Immunotherapy. <i>Advanced Therapeutics</i> , 2020, 3, 2000093.	1.6	26

#	ARTICLE	IF	CITATIONS
255	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 369-378.	1.2	10
256	Tumor-Derived Extracellular Vesicles and the Immune System—Lessons From Immune-Competent Mouse-Tumor Models. <i>Frontiers in Immunology</i> , 2020, 11, 606859.	2.2	13
257	Exosomes and breast cancer drug resistance. <i>Cell Death and Disease</i> , 2020, 11, 987.	2.7	103
258	High-throughput single-EV liquid biopsy: Rapid, simultaneous, and multiplexed detection of nucleic acids, proteins, and their combinations. <i>Science Advances</i> , 2020, 6, .	4.7	73
259	Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 594514.	1.3	10
260	The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8689.	1.8	38
261	Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research. <i>Frontiers in Oncology</i> , 2020, 10, 568174.	1.3	14
262	Emerging Role of Extracellular Vesicles in Immune Regulation and Cancer Progression. <i>Cancers</i> , 2020, 12, 3563.	1.7	44
263	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
264	A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580140.	1.8	10
265	Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1-mediated immunoescape via STING-IFN signaling and extracellular vesicles. , 2020, 8, e001372.		77
266	Recent Advancements in the Loading and Modification of Therapeutic Exosomes. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 586130.	2.0	81
267	Immune Regulation by Dendritic Cell Extracellular Vesicles in Cancer Immunotherapy and Vaccines. <i>Cancers</i> , 2020, 12, 3558.	1.7	35
268	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020, 12, 3625.	1.7	27
269	&lt;p&gt;MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 12215-12223.	0.9	20
270	Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. <i>Scientific Reports</i> , 2020, 10, 19296.	1.6	39
271	Isolation and characterization of exosomes for cancer research. <i>Journal of Hematology and Oncology</i> , 2020, 13, 152.	6.9	218
272	The Influence of Tumor Microenvironment on Immune Escape of Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8359.	1.8	70



#	ARTICLE	IF	CITATIONS
273	Rational Synthesis of Aptamer-Functionalized Polyethylenimine-Modified Magnetic Graphene Oxide Composites for Highly Efficient Enrichment and Comprehensive Metabolomics Analysis of Exosomes. <i>Analytical Chemistry</i> , 2020, 92, 15497-15505.	3.2	24
274	Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2372-2386.	2.6	32
275	Exosome-derived ENO1 regulates integrin $\alpha 6 \beta 4$ expression and promotes hepatocellular carcinoma growth and metastasis. <i>Cell Death and Disease</i> , 2020, 11, 972.	2.7	56
276	Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1047-1059.	1.5	11
277	Proteomic analysis of pancreatic ductal adenocarcinoma. <i>Expert Review of Proteomics</i> , 2020, 17, 453-467.	1.3	5
278	Advances of exosome isolation techniques in lung cancer. <i>Molecular Biology Reports</i> , 2020, 47, 7229-7251.	1.0	17
279	Precision Detection Technology: Equipping Precision Oncology with Wings. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	5
280	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2020, 11, 1612.	2.2	21
281	Exosomes: Biological Carriers and Promising Tools for Cancer Immunotherapy. <i>Vaccines</i> , 2020, 8, 390.	2.1	5
282	Nanozyme-assisted sensitive profiling of exosomal proteins for rapid cancer diagnosis. <i>Theranostics</i> , 2020, 10, 9303-9314.	4.6	44
283	The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study. <i>Frontiers in Oncology</i> , 2020, 10, 1317.	1.3	18
284	Therapeutic Potentials of Extracellular Vesicles for the Treatment of Diabetes and Diabetic Complications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5163.	1.8	25
285	Cancer-associated fibroblasts-derived exosomal miR-17-5p promotes colorectal cancer aggressive phenotype by initiating a RUNX3/MYC/TGF- $\beta 1$ positive feedback loop. <i>Cancer Letters</i> , 2020, 491, 22-35.	3.2	59
286	Microvesicles in Cancer: Small Size, Large Potential. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5373.	1.8	44
287	Small Extracellular Vesicles Isolated from Serum May Serve as Signal-Enhancers for the Monitoring of CNS Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5359.	1.8	21
288	Application of exosomes as liquid biopsy in clinical diagnosis. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 144.	7.1	396
289	Electrochemical aptasensor for exosomal proteins profiling based on DNA nanotetrahedron coupled with enzymatic signal amplification. <i>Analytica Chimica Acta</i> , 2020, 1130, 1-9.	2.6	35
290	Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks. <i>Biosensors and Bioelectronics</i> , 2020, 166, 112452.	5.3	61

#	ARTICLE	IF	CITATIONS
291	The Convergence of Extracellular Vesicle and GPCR Biology. Trends in Pharmacological Sciences, 2020, 41, 627-640.	4.0	21
292	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Cancers, 2020, 12, 1945.	1.7	49
293	Focus on the morphogenesis, fate and the role in tumor progression of multivesicular bodies. Cell Communication and Signaling, 2020, 18, 122.	2.7	22
294	Targeting immune checkpoints in hematological malignancies. Journal of Hematology and Oncology, 2020, 13, 111.	6.9	66
295	Mechanisms of Cancer Resistance to Immunotherapy. Frontiers in Oncology, 2020, 10, 1290.	1.3	159
296	Upregulation of circ_0000199 in circulating exosomes is associated with survival outcome in OSCC. Scientific Reports, 2020, 10, 13739.	1.6	37
297	Biology and therapeutic potential of mesenchymal stem cell-derived exosomes. Cancer Science, 2020, 111, 3100-3110.	1.7	130
298	EV-origin: Enumerating the tissue-cellular origin of circulating extracellular vesicles using exLR profile. Computational and Structural Biotechnology Journal, 2020, 18, 2851-2859.	1.9	67
299	Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients. Pilot and Feasibility Studies, 2020, 6, 154.	0.5	4
300	Role of microenvironmental acidity and tumor exosomes in cancer immunomodulation. Translational Cancer Research, 2020, 9, 5775-5786.	0.4	9
301	T cell-derived exosomes induced macrophage inflammatory protein-1 $\beta$ drive the trafficking of CD8 <sup>+</sup> T cells in oral lichen planus. Journal of Cellular and Molecular Medicine, 2020, 24, 14086-14098.	1.6	13
302	Diagnostic and Therapeutic Potential of Extracellular Vesicles in B-Cell Malignancies. Frontiers in Oncology, 2020, 10, 580874.	1.3	17
303	Tailoring precision immunotherapy: coming to a clinic soon?. ESMO Open, 2020, 5, e000631.	2.0	8
304	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker Research, 2020, 8, 34.	2.8	266
305	New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells, 2020, 9, 1967.	1.8	15
306	High-Fidelity Determination and Tracing of Small Extracellular Vesicle Cargoes. Small, 2020, 16, e2002800.	5.2	21
307	Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034.	6.1	77
308	Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets. Cancer Biology and Medicine, 2020, 17, 583-598.	1.4	6

#	ARTICLE	IF	CITATIONS
309	The evolving translational potential of small extracellular vesicles in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 697-709.	12.8	295
310	Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. <i>Biomaterials</i> , 2020, 263, 120380.	5.7	11
311	Small extracellular vesicle-bound vascular endothelial growth factor secreted by carcinoma-associated fibroblasts promotes angiogenesis in a bevacizumab-resistant manner. <i>Cancer Letters</i> , 2020, 492, 71-83.	3.2	32
312	Hypoxic Tumor-Derived Exosomal Long Noncoding RNA UCA1 Promotes Angiogenesis via miR-96-5p/AMOTL2 in Pancreatic Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 179-195.	2.3	117
313	Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles. <i>Frontiers in Immunology</i> , 2020, 11, 1867.	2.2	7
314	Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 1455.	1.3	9
315	Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2620.	1.7	21
316	Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. <i>Nature Reviews Endocrinology</i> , 2020, 16, 590-607.	4.3	43
317	Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 149.	3.5	208
318	Normoxic Tumour Extracellular Vesicles Modulate the Response of Hypoxic Cancer and Stromal Cells to Doxorubicin In Vitro. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5951.	1.8	3
319	Extracellular Vesicles in the Development of Cancer Therapeutics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6097.	1.8	40
320	Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 141.	7.1	34
321	Cytokine-related genes play critical roles in extrafollicular growth of follicular lymphoma cells. <i>Hematological Oncology</i> , 2020, 38, 673-679.	0.8	2
322	An ultrasensitive hybridization chain reaction-amplified CRISPR-Cas12a aptasensor for extracellular vesicle surface protein quantification. <i>Theranostics</i> , 2020, 10, 10262-10273.	4.6	85
323	Do tumor exosome integrins alone determine organotropic metastasis?. <i>Molecular Biology Reports</i> , 2020, 47, 8145-8157.	1.0	25
324	Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 2592.	1.7	8
325	Validation of plasma-derived small extracellular vesicles as cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 719-720.	12.5	18
326	Integration of individual prediction index based on autophagy-related genes and clinical phenomes in melanoma patients. <i>Clinical and Translational Medicine</i> , 2020, 10, e132.	1.7	4

#	ARTICLE	IF	CITATIONS
327	Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. <i>Scientific Reports</i> , 2020, 10, 14749.	1.6	44
328	The role of extracellular vesicles in cholangiocarcinoma. <i>Cancer Cell International</i> , 2020, 20, .	1.8	7
329	Autophagy controls mesenchymal stem cell therapy in psychological stress colitis mice. <i>Autophagy</i> , 2021, 17, 2586-2603.	4.3	15
330	Tumor-derived exosomes facilitate tumor cells escape from drug therapy in clear cell renal cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 3416-3425.	0.4	6
331	The future of Extracellular Vesicles as Theranostics – an ISEV meeting report. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1809766.	5.5	77
332	&lt;p&gt;A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 6493-6509.	0.9	19
333	The crosstalk: exosomes and lipid metabolism. <i>Cell Communication and Signaling</i> , 2020, 18, 119.	2.7	93
334	An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8+ T Cells is Dependent on IL-10 and Independent of BRAFV600E Mutation in Melanoma Cell Lines. <i>Immunological Investigations</i> , 2020, 49, 744-757.	1.0	13
335	Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer. , 2020, 8, e000667.		24
336	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. , 2020, 8, e001113.		32
337	HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses. <i>Cancers</i> , 2020, 12, 3759.	1.7	25
338	Extracellular Vesicles Orchestrate Immune and Tumor Interaction Networks. <i>Cancers</i> , 2020, 12, 3696.	1.7	12
339	Growing Evidence of Exosomal MicroRNA-Related Metastasis of Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	8
340	Circulating Melanoma-Derived Extracellular Vesicles: Impact on Melanoma Diagnosis, Progression Monitoring, and Treatment Response. <i>Pharmaceuticals</i> , 2020, 13, 475.	1.7	13
341	COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12004.	5.5	43
342	ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis. <i>Biophysics Reports</i> , 2020, 6, 290-298.	0.2	2
343	Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity. <i>Biomedicines</i> , 2020, 8, 562.	1.4	13
344	Exosomes: Emerging Diagnostic and Therapeutic Targets in Cutaneous Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9264.	1.8	18

#	ARTICLE	IF	CITATIONS
345	Size-Exclusion Chromatography as a Technique for the Investigation of Novel Extracellular Vesicles in Cancer. <i>Cancers</i> , 2020, 12, 3156.	1.7	23
346	ExoTracker: a low-pH-activatable fluorescent probe for labeling exosomes and monitoring endocytosis and trafficking. <i>Chemical Communications</i> , 2020, 56, 14869-14872.	2.2	11
347	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. <i>Karger Kompass Dermatologie</i> , 2020, 8, 92-101.	0.0	0
348	Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3197.	1.7	16
349	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	0.8	11
350	Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. <i>Karger Kompass Pneumologie</i> , 2020, 8, 300-317.	0.0	1
351	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569219.	1.8	59
352	One-Step RT-PCR for Detection of Micrnas in Exosomes Using Droplet Microfluidics. , 2020, , .		1
353	Preparation of engineered extracellular vesicles with full-length functional PD-1 membrane proteins by baculovirus expression system. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 967-972.	1.0	7
354	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Oncolmunology</i> , 2020, 9, 1744980.	2.1	77
355	Milk-Derived Extracellular Vesicles in Inter-Organism, Cross-Species Communication and Drug Delivery. <i>Proteomes</i> , 2020, 8, 11.	1.7	86
356	Current Molecular Markers of Melanoma and Treatment Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3535.	1.8	45
357	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
358	Immune Escape Mediated by Exosomal PD-L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
359	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 109996.	2.5	35
360	Saliva exosomes-derived UBE2O mRNA promotes angiogenesis in cutaneous wounds by targeting SMAD6. <i>Journal of Nanobiotechnology</i> , 2020, 18, 68.	4.2	45
361	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	1.7	14
362	Extracellular Vesicles From Gastric Cancer Cells Induce PD-L1 Expression on Neutrophils to Suppress T-Cell Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 629.	1.3	38

#	ARTICLE	IF	CITATIONS
364	Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes. <i>Cancers</i> , 2020, 12, 1386.	1.7	29
365	Acquired Resistance to Immune Checkpoint Blockade Therapies. <i>Cancers</i> , 2020, 12, 1161.	1.7	9
366	Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. <i>PLoS ONE</i> , 2020, 15, e0232545.	1.1	19
367	CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. <i>Frontiers in Immunology</i> , 2020, 11, 1109.	2.2	165
368	CRISPR screen in mechanism and target discovery for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188378.	3.3	25
369	Breast Cancer Derived Extracellular Vesicles in Bone Metastasis Induction and Their Clinical Implications as Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3573.	1.8	26
370	THE PRESENT AND FUTURE OF THE MASS SPECTROMETRY-BASED INVESTIGATION OF THE EXOSOME LANDSCAPE. <i>Mass Spectrometry Reviews</i> , 2020, 39, 745-762.	2.8	18
371	Biogenic nanoparticles as immunomodulator for tumor treatment. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1646.	3.3	21
372	Immune checkpoint signaling and cancer immunotherapy. <i>Cell Research</i> , 2020, 30, 660-669.	5.7	617
373	EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2970-e2981.	1.8	15
374	Extracellular Vesicles in Renal Cell Carcinoma: Multifaceted Roles and Potential Applications Identified by Experimental and Computational Methods. <i>Frontiers in Oncology</i> , 2020, 10, 724.	1.3	18
375	Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy. <i>Trends in Cancer</i> , 2020, 6, 550-558.	3.8	94
376	Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. <i>Molecular Psychiatry</i> , 2021, 26, 5140-5149.	4.1	59
377	Proteomic Identification Reveals the Role of Ciliary Extracellular-Like Vesicle in Cardiovascular Function. <i>Advanced Science</i> , 2020, 7, 1903140.	5.6	13
378	Extracellular vesicle long non-coding RNAs and circular RNAs: Biology, functions and applications in cancer. <i>Cancer Letters</i> , 2020, 489, 111-120.	3.2	37
379	Proposed mechanisms for the extracellular release of PD-L1 by the anticancer saponin platycodin D. <i>International Immunopharmacology</i> , 2020, 85, 106675.	1.7	14
380	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 595-610.	12.5	124
381	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093033.	1.4	25

#	ARTICLE	IF	CITATIONS
382	Extracellular Vesicles in the Tumor Microenvironment: Various Implications in Tumor Progression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1259, 155-170.	0.8	11
383	Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells. <i>Molecular Cancer</i> , 2020, 19, 101.	7.9	190
384	Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1. <i>Journal of Translational Medicine</i> , 2020, 18, 220.	1.8	20
385	Nanoparticle-based biosensors for detection of extracellular vesicles in liquid biopsies. <i>Journal of Materials Chemistry B</i> , 2020, 8, 6710-6738.	2.9	32
386	Tumor-Derived Exosomes in Immunosuppression and Immunotherapy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	85
387	3D Immunocompetent Organ-on-a-Chip Models. <i>Small Methods</i> , 2020, 4, 2000235.	4.6	40
389	Multivalence-Actuated DNA Nanomachines Enable Bicolor Exosomal Phenotyping and PD-L1-Guided Therapy Monitoring. <i>Analytical Chemistry</i> , 2020, 92, 9877-9886.	3.2	38
390	Diagnostic and Therapeutic Applications of Exosomes in Cancer with a Special Focus on Head and Neck Squamous Cell Carcinoma (HNSCC). <i>International Journal of Molecular Sciences</i> , 2020, 21, 4344.	1.8	20
391	Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. <i>Scientific Reports</i> , 2020, 10, 9077.	1.6	36
392	Modulating Cytokine Production via Select Packaging and Secretion From Extracellular Vesicles. <i>Frontiers in Immunology</i> , 2020, 11, 1040.	2.2	48
393	Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. <i>Frontiers in Oncology</i> , 2020, 10, 760.	1.3	33
394	The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4072.	1.8	48
395	Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1. <i>Hematological Oncology</i> , 2020, 38, 467-477.	0.8	9
396	Exosome-Containing Preparations From Postirradiated Mouse Melanoma Cells Delay Melanoma Growth In Vivo by a Natural Killer Cell-Dependent Mechanism. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 104-114.	0.4	22
397	Proteomic Analysis of Exosomes from Adipose-Derived Mesenchymal Stem Cells: A Novel Therapeutic Strategy for Tissue Injury. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	32
398	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
399	Extracellular vesicle isolation from human renal cancer tissue. <i>Medical Oncology</i> , 2020, 37, 28.	1.2	23
400	The function and clinical application of extracellular vesicles in innate immune regulation. <i>Cellular and Molecular Immunology</i> , 2020, 17, 323-334.	4.8	171

#	ARTICLE	IF	CITATIONS
401	A Novel Model of Cancer Drug Resistance: Oncosomal Release of Cytotoxic and Antibody-Based Drugs. <i>Biology</i> , 2020, 9, 47.	1.3	20
402	Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 155.	1.8	32
403	&lt;p&gt;High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1757-1765.	1.0	8
404	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
405	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
406	Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle. <i>Trends in Cancer</i> , 2020, 6, 506-517.	3.8	95
407	Results of a Randomized Phase IIb Trial of Nelinepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2515-2523.	3.2	58
408	p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. <i>Oncogene</i> , 2020, 39, 3939-3951.	2.6	70
409	Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2118.	1.8	79
410	EV-Ident: Identifying Tumor-Specific Extracellular Vesicles by Size Fractionation and Single-Vesicle Analysis. <i>Analytical Chemistry</i> , 2020, 92, 6010-6018.	3.2	22
411	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
412	Long Noncoding RNA MRPL23-AS1 Promotes Adenoid Cystic Carcinoma Lung Metastasis. <i>Cancer Research</i> , 2020, 80, 2273-2285.	0.4	43
413	Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 90.	1.3	30
414	Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer. <i>Cells</i> , 2020, 9, 564.	1.8	42
415	Nanosponges of circulating tumor-derived exosomes for breast cancer metastasis inhibition. <i>Biomaterials</i> , 2020, 242, 119932.	5.7	77
416	Aptamer-guided extracellular vesicle theranostics in oncology. <i>Theranostics</i> , 2020, 10, 3849-3866.	4.6	45
417	Clinical applications of exosome membrane proteins. <i>Precision Clinical Medicine</i> , 2020, 3, 54-66.	1.3	101
418	Predictive biomarkers of drug resistance in colorectal cancer&quot;Recent updates. , 2020, , 135-151.		1



#	ARTICLE	IF	CITATIONS
419	Tumor-derived extracellular vesicles: Regulators of tumor microenvironment and the enlightenment in tumor therapy. <i>Pharmacological Research</i> , 2020, 159, 105041.	3.1	16
420	Biogenesis, Biologic Function and Clinical Potential of Exosomes in Different Diseases. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 4428.	1.3	12
421	Perspectives in Manipulating EVs for Therapeutic Applications: Focus on Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4623.	1.8	19
422	Extracellular Vesicles in Viral Infections of the Nervous System. <i>Viruses</i> , 2020, 12, 700.	1.5	22
423	Extracellular Vesicles in Cancer Metastasis: Potential as Therapeutic Targets and Materials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4463.	1.8	50
424	Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. <i>Oncolmunology</i> , 2020, 9, 1773205.	2.1	3
425	PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2402-2409.	4.8	23
427	Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy. <i>Cells</i> , 2020, 9, 1518.	1.8	35
428	Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas. <i>Trends in Cancer</i> , 2020, 6, 910-923.	3.8	17
429	Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. <i>Laboratory Investigation</i> , 2020, 100, 1503-1516.	1.7	27
430	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	2.6	89
431	The biology <b>,</b> function <b>,</b> and biomedical applications of exosomes. <i>Science</i> , 2020, 367, .	6.0	4,742
432	Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids. <i>Hno</i> , 2020, 68, 100-105.	0.4	15
433	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , 2020, 12, 361.	1.7	19
434	The emerging development of tumor mutational burden in patients with NSCLC. <i>Future Oncology</i> , 2020, 16, 469-481.	1.1	2
435	Aptamer-Based Liquid Biopsy. <i>ACS Applied Bio Materials</i> , 2020, 3, 2743-2764.	2.3	38
436	The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention. <i>Journal of Leukocyte Biology</i> , 2020, 107, 731-738.	1.5	21
437	Tracking the evolution of circulating exosomal PD-L1 to monitor melanoma patients. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1710899.	5.5	175

#	ARTICLE	IF	CITATIONS
438	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
439	The importance of exosomal PDL1 in tumour immune evasion. <i>Nature Reviews Immunology</i> , 2020, 20, 209-215.	10.6	360
440	Unraveling the mechanisms that specify molecules for secretion in extracellular vesicles. <i>Methods</i> , 2020, 177, 15-26.	1.9	50
441	Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles. <i>Cells</i> , 2020, 9, 130.	1.8	21
442	Melatonin alleviates vascular calcification and ageing through exosomal miR-204/miR-211 cluster in a paracrine manner. <i>Journal of Pineal Research</i> , 2020, 68, e12631.	3.4	98
443	Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. <i>Molecular Cancer</i> , 2020, 19, 19.	7.9	180
444	Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction. <i>Angewandte Chemie</i> , 2020, 132, 4830-4835.	1.6	36
445	Communication in tiny packages: Exosomes as means of tumor-stroma communication. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188340.	3.3	51
446	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
447	Extracellular Vesicles and Cancer: A Focus on Metabolism, Cytokines, and Immunity. <i>Cancers</i> , 2020, 12, 171.	1.7	38
449	Intrinsic Genetic and Transcriptomic Patterns Reflect Tumor Immune Subtypes Facilitating Exploring Possible Combinatory Therapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 53.	1.6	1
450	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 492.	1.3	33
451	Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer. <i>Cells</i> , 2020, 9, 814.	1.8	23
452	The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. <i>Journal of Leukocyte Biology</i> , 2020, 108, 363-376.	1.5	40
453	Contributing to liquid biopsy: Optical and electrochemical methods in cancer biomarker analysis. <i>Coordination Chemistry Reviews</i> , 2020, 415, 213317.	9.5	28
454	Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes. <i>PLoS ONE</i> , 2020, 15, e0231430.	1.1	24
455	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102949.	2.0	20
456	Learning from clinical trials of neoadjuvant checkpoint blockade. <i>Nature Medicine</i> , 2020, 26, 475-484.	15.2	107

#	ARTICLE	IF	CITATIONS
457	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CART Cell Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 531.	2.2	20
458	The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 604.	2.2	51
459	PD-L1â€“PD-1 Pathway in the Pathophysiology of Multiple Myeloma. <i>Cancers</i> , 2020, 12, 924.	1.7	41
460	Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 960.	1.7	25
461	Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. <i>Theranostics</i> , 2020, 10, 4544-4556.	4.6	85
462	Bargain with the tooth fairy â€“ The savings accounts for dental stem cells. <i>Biomedical Journal</i> , 2020, 43, 99-106.	1.4	3
463	Inclusion of PD-L1 into a recombinant profilin antigen enhances immunity against <i>Babesia microti</i> in a murine model. <i>Ticks and Tick-borne Diseases</i> , 2020, 11, 101446.	1.1	3
464	Exosomes as Sentinels against Bacterial Pathogens. <i>Developmental Cell</i> , 2020, 53, 138-139.	3.1	7
465	Exosomal PD-L1 induces immunosuppressive nonclassical monocytes. <i>Neuro-Oncology</i> , 2020, 22, 901-902.	0.6	5
466	Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 162.	1.8	21
467	Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 166.	1.8	71
468	Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors. <i>Frontiers in Immunology</i> , 2020, 11, 262.	2.2	87
469	Hyperprogression Under Immune Checkpoint-Based Immunotherapyâ€“Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. <i>Cancers</i> , 2020, 12, 804.	1.7	19
470	Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2286.	1.8	61
471	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2367.	1.8	34
472	Crossâ€“talk between tumors at anatomically distinct sites. <i>FEBS Journal</i> , 2021, 288, 81-90.	2.2	9
473	Engineering in Medicine To Address the Challenge of Cancer Drug Resistance: From Micro- and Nanotechnologies to Computational and Mathematical Modeling. <i>Chemical Reviews</i> , 2021, 121, 3352-3389.	23.0	41
474	Extracellular vesicleâ€“associated organotropic metastasis. <i>Cell Proliferation</i> , 2021, 54, e12948.	2.4	36

#	ARTICLE	IF	CITATIONS
475	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
476	Non-coding RNA derived from extracellular vesicles in cancer immune escape: Biological functions and potential clinical applications. <i>Cancer Letters</i> , 2021, 501, 234-246.	3.2	20
477	Downregulation of Interferon- $\gamma$ Receptor Expression Endows Resistance to Anti-Programmed Death Protein 1 Therapy in Colorectal Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 21-28.	1.3	5
478	Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine</i> , 2021, 71, 242-252.	1.1	5
479	Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery. <i>Bioactive Materials</i> , 2021, 6, 749-756.	8.6	22
480	Cancer evolution: A means by which tumors evade treatment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111016.	2.5	20
481	Enrichment of circulating tumor-derived extracellular vesicles from human plasma. <i>Journal of Immunological Methods</i> , 2021, 490, 112936.	0.6	19
482	Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis. <i>Targeted Oncology</i> , 2021, 16, 13-26.	1.7	15
483	Biological role and clinical relevance of extracellular vesicles as key mediators of cell communication in cancer. <i>Advances in Biomembranes and Lipid Self-Assembly</i> , 2021, 33, 37-117.	0.3	4
484	Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering. <i>Advanced Science</i> , 2021, 8, 2003505.	5.6	192
485	Tumor-derived exosomes in the PD-L1/PD-L1 axis: Significant regulators as well as promising clinical targets. <i>Journal of Cellular Physiology</i> , 2021, 236, 4138-4151.	2.0	17
486	Engineering approaches for effective therapeutic applications based on extracellular vesicles. <i>Journal of Controlled Release</i> , 2021, 330, 15-30.	4.8	45
487	Extracellular vesicles and oncogenic signaling. <i>Molecular Oncology</i> , 2021, 15, 3-26.	2.1	30
488	The Yin and Yang of tumour-derived extracellular vesicles in tumour immunity. <i>Journal of Biochemistry</i> , 2021, 169, 155-161.	0.9	2
489	The emerging role of miR-128 in musculoskeletal diseases. <i>Journal of Cellular Physiology</i> , 2021, 236, 4231-4243.	2.0	14
490	The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.	4.8	102
491	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 131-140.	3.2	93
492	Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 459-468.	1.2	4

#	ARTICLE	IF	CITATIONS
493	The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. <i>International Journal of Cancer</i> , 2021, 148, 2640-2651.	2.3	90
494	The role of hypoxia-inducible factor 1 in tumor immune evasion. <i>Medicinal Research Reviews</i> , 2021, 41, 1622-1643.	5.0	157
495	Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. <i>Cell</i> , 2021, 184, 404-421.e16.	13.5	399
496	The forces driving cancer extracellular vesicle secretion. <i>Neoplasia</i> , 2021, 23, 149-157.	2.3	43
497	CAR-T cell engineering with CCR6 exhibits superior anti-solid tumor efficacy. <i>Science Bulletin</i> , 2021, 66, 755-756.	4.3	3
498	Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect. <i>Journal of Materials Chemistry B</i> , 2021, 9, 746-756.	2.9	27
499	One-step quantification of salivary exosomes based on combined aptamer recognition and quantum dot signal amplification. <i>Biosensors and Bioelectronics</i> , 2021, 171, 112733.	5.3	45
500	A facile "one-material" strategy for tandem enrichment of small extracellular vesicles phosphoproteome. <i>Talanta</i> , 2021, 223, 121776.	2.9	8
501	Extracellular-vesicles delivered tumor-specific sequential nanocatalysts can be used for MRI-informed nanocatalytic Therapy of hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 64-78.	4.6	17
502	Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188463.	3.3	16
503	The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 241-258.	1.4	29
504	Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	147
505	Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival. <i>Journal of Applied Statistics</i> , 2021, 48, 1352-1373.	0.6	3
506	Small extracellular vesicles (sEVs): discovery, functions, applications, detection methods and various engineered forms. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 371-394.	1.4	20
507	Trophoblastic extracellular vesicles and viruses: Friends or foes?. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13345.	1.2	4
508	Exosomes as mediators of immune regulation and immunotherapy in cancer. <i>FEBS Journal</i> , 2021, 288, 10-35.	2.2	110
509	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 867-887.	2.4	9
510	Reinvigorating exhausted CD8 <sup>+</sup> cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56

#	ARTICLE	IF	CITATIONS
511	Extracellular vesicles in cancer nanomedicine. <i>Seminars in Cancer Biology</i> , 2021, 69, 212-225.	4.3	69
512	Immune checkpoint: The novel target for antitumor therapy. <i>Genes and Diseases</i> , 2021, 8, 25-37.	1.5	27
513	PD-L1 status in breast cancer: Current view and perspectives. <i>Seminars in Cancer Biology</i> , 2021, 72, 146-154.	4.3	69
514	Toward Clinical Application of Exosomes for Cancer Diagnosis. <i>Oleoscience</i> , 2021, 21, 63-68.	0.0	0
515	BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells. <i>Oncogene</i> , 2021, 40, 1516-1530.	2.6	14
516	Tumor-derived exosomal circFARSA mediates M2 macrophage polarization via the PTEN/PI3K/AKT pathway to promote non-small cell lung cancer metastasis. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100412.	0.7	36
517	Significance of trogocytosis and exosome-mediated transport in establishing and maintaining the tumor microenvironment in lymphoid malignancies. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 192-201.	0.3	4
518	Extracellular Vesicles in Liquid Biopsies: Potential for Disease Diagnosis. <i>BioMed Research International</i> , 2021, 2021, 1-17.	0.9	22
519	The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas. <i>Diagnostics</i> , 2021, 11, 196.	1.3	24
520	Ancient Evolutionary Origin and Properties of Universally Produced Natural Exosomes Contribute to Their Therapeutic Superiority Compared to Artificial Nanoparticles. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1429.	1.8	18
521	Proteomic Landscape of Exosomes Reveals the Functional Contributions of CD151 in Triple-Negative Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100121.	2.5	39
522	Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2007293.	11.1	106
523	Multifunctional Applications of Engineered Extracellular Vesicles in the Treatment of Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	16
524	Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways. <i>Molecular Biomedicine</i> , 2021, 2, 3.	1.7	42
525	Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors. <i>In Vivo</i> , 2021, 35, 1277-1283.	0.6	9
526	ANGPTL2-containing small extracellular vesicles from vascular endothelial cells accelerate leukemia progression. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	28
527	Preparation of Sm-doped CaZrO <sub>3</sub> nanosheets for facile human serum exosome isolation. <i>New Journal of Chemistry</i> , 2021, 45, 11719-11726.	1.4	4
528	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. <i>Nature Communications</i> , 2021, 12, 346.	5.8	107

#	ARTICLE	IF	CITATIONS
529	Extracellular Vesicles Regulate Cancer Metastasis. <i>Sub-Cellular Biochemistry</i> , 2021, 97, 275-296.	1.0	4
530	Emerging Significance and Therapeutic Potential of Extracellular vesicles. <i>International Journal of Biological Sciences</i> , 2021, 17, 2476-2486.	2.6	18
531	Exosomes in cancer. <i>Advances in Clinical Chemistry</i> , 2021, 101, 1-40.	1.8	13
532	Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer. <i>Oncologie</i> , 2021, 23, 335-350.	0.2	1
533	Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. , 2021, 9, e001698.		78
534	Tumor-derived Exosome Promotes Metastasis via Altering its Phenotype and Inclusions. <i>Journal of Cancer</i> , 2021, 12, 4240-4246.	1.2	7
535	Salting the Soil: Targeting the Microenvironment of Brain Metastases. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 455-466.	1.9	13
536	PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation. <i>Biomaterials Science</i> , 2021, 9, 1246-1255.	2.6	9
537	Stem Cell Based Exosomes: Are They Effective in Disease or Health?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1341, 45-65.	0.8	0
538	Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis. <i>Oncolmmunology</i> , 2021, 10, 1938476.	2.1	14
539	Immunoassay-aptasensor for the determination of tumor-derived exosomes based on the combination of magnetic nanoparticles and hybridization chain reaction. <i>RSC Advances</i> , 2021, 11, 4983-4990.	1.7	13
540	Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis. <i>Theranostics</i> , 2021, 11, 7144-7158.	4.6	21
541	Small extracellular vesiclesâ€based cellâ€free strategies for therapy. <i>MedComm</i> , 2021, 2, 17-26.	3.1	9
542	Autophagy Blockade Limits HER2+ Breast Cancer Tumorigenesis by Perturbing HER2 Trafficking and Promoting Release Via Small Extracellular Vesicles. <i>Developmental Cell</i> , 2021, 56, 341-355.e5.	3.1	25
543	PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas. <i>Frontiers in Immunology</i> , 2021, 12, 628966.	2.2	33
544	ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer. <i>Translational Oncology</i> , 2021, 14, 101003.	1.7	7
545	Engineering Exosome-Like Nanovesicles Derived from <i>Asparagus cochinchinensis</i> Can Inhibit the Proliferation of Hepatocellular Carcinoma Cells with Better Safety Profile. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1575-1586.	3.3	75
546	Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 606906.	1.3	36

#	ARTICLE	IF	CITATIONS
547	Exosomes in Breast Cancer – Mechanisms of Action and Clinical Potential. <i>Molecular Cancer Research</i> , 2021, 19, 935-945.	1.5	18
548	Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 780.	1.7	40
549	New Insights Into the Cancer – Microbiome – Immune Axis: Decrypting a Decade of Discoveries. <i>Frontiers in Immunology</i> , 2021, 12, 622064.	2.2	91
550	Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy. <i>AAPS Journal</i> , 2021, 23, 30.	2.2	22
551	Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. <i>Cancer Discovery</i> , 2021, 11, 560-574.	7.7	12
552	WJMSC – derived small extracellular vesicle enhance T cell suppression through PD – L1. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12067.	5.5	39
553	Extracellular Vesicles: Emerging Modulators of Cancer Drug Resistance. <i>Cancers</i> , 2021, 13, 749.	1.7	39
554	Exosomes and Cell Communication: From Tumour-Derived Exosomes and Their Role in Tumour Progression to the Use of Exosomal Cargo for Cancer Treatment. <i>Cancers</i> , 2021, 13, 822.	1.7	40
555	DNA Methylation Analysis to Unravel Altered Genetic Pathways Underlying Early Onset and Late Onset Neonatal Sepsis. A Pilot Study. <i>Frontiers in Immunology</i> , 2021, 12, 622599.	2.2	14
556	Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 585.	1.7	25
557	Tracing Tumor – Derived Exosomal PD – L1 by Dual – Aptamer Activated Proximity – Induced Droplet Digital PCR. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 7582-7586.	7.2	117
559	Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2142.	1.8	6
560	Proteomic profile of melanoma cell – derived small extracellular vesicles in patients – plasma: a potential correlate of melanoma progression. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12063.	5.5	38
561	miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells. <i>Cancers</i> , 2021, 13, 618.	1.7	20
562	Unexpected PD – L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. <i>EMBO Molecular Medicine</i> , 2021, 13, e12716.	3.3	12
563	Advances in Analytical Technologies for Extracellular Vesicles. <i>Analytical Chemistry</i> , 2021, 93, 4739-4774.	3.2	53
565	Rab22a-Neof1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 59.	7.1	45
566	A Comprehensive Review on Factors Influences Biogenesis, Functions, Therapeutic and Clinical Implications of Exosomes. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1281-1312.	3.3	141



#	ARTICLE	IF	CITATIONS
567	Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. , 2021, 9, e002100.		29
568	Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. <i>Frontiers in Oncology</i> , 2020, 10, 626129.	1.3	48
569	Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR. <i>Angewandte Chemie</i> , 2021, 133, 7660-7664.	1.6	5
570	Exosomes in cancer development. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 83-92.	1.5	26
571	Integrin Regulation in Immunological and Cancerous Cells and Exosomes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2193.	1.8	26
572	Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	29
573	Raman Spectral Signatures of Serum-Derived Extracellular Vesicle-Enriched Isolates May Support the Diagnosis of CNS Tumors. <i>Cancers</i> , 2021, 13, 1407.	1.7	10
574	Exosomal long non-coding RNAs in the diagnosis and oncogenesis of pancreatic cancer. <i>Cancer Letters</i> , 2021, 501, 55-65.	3.2	22
575	Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 650481.	1.3	23
576	Extracellular vesicles in immunomodulation and tumor progression. <i>Nature Immunology</i> , 2021, 22, 560-570.	7.0	233
577	Exosomes and cancer: from molecular mechanisms to clinical applications. <i>Medical Oncology</i> , 2021, 38, 45.	1.2	48
578	Mesenchymal Stromal Cell-Mediated Immune Regulation: A Promising Remedy in the Therapy of Type 2 Diabetes Mellitus. <i>Stem Cells</i> , 2021, 39, 838-852.	1.4	14
579	Microfluidic detection of human diseases: From liquid biopsy to COVID-19 diagnosis. <i>Journal of Biomechanics</i> , 2021, 117, 110235.	0.9	22
580	Bioorthogonally surface-edited extracellular vesicles based on metabolic glycoengineering for CD44-mediated targeting of inflammatory diseases. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12077.	5.5	30
581	Could Extracellular Vesicles Contribute to Generation or Awakening of "Sleepy" Metastatic Niches?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 625221.	1.8	11
582	Aptamer-Based Detection of Circulating Targets for Precision Medicine. <i>Chemical Reviews</i> , 2021, 121, 12035-12105.	23.0	294
583	Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor-Immune Interactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3374.	1.8	9
584	Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer. , 2021, 9, e002218.		9

#	ARTICLE	IF	CITATIONS
585	The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?. <i>Biomarker Research</i> , 2021, 9, 22.	2.8	13
586	Epithelium- and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response. <i>Cell Death and Differentiation</i> , 2021, 28, 2238-2256.	5.0	33
587	Aptamer-Exosomes for Tumor Theranostics. <i>ACS Sensors</i> , 2021, 6, 1418-1429.	4.0	20
588	Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. <i>Cancer Immunology Research</i> , 2021, 9, 568-582.	1.6	30
589	PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B. <i>Cancer Science</i> , 2021, 112, 1878-1887.	1.7	6
590	Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 653846.	1.3	2
591	Restoring Tissue Homeostasis at Metastatic Sites: A Focus on Extracellular Vesicles in Bone Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 644109.	1.3	13
592	HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. <i>Oncogene</i> , 2021, 40, 2230-2242.	2.6	26
593	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 1402.	5.8	85
594	Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 508-518.	2.0	21
595	Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. <i>Clinical Cancer Research</i> , 2021, 27, 3253-3264.	3.2	26
596	S1 nuclease digestion-based rational truncation of PD-L1 aptamer and establishment of a signal dual amplification aptasensor. <i>Sensors and Actuators B: Chemical</i> , 2021, 331, 129442.	4.0	20
597	Microfluidics for Liquid Biopsies: Recent Advances, Current Challenges, and Future Directions. <i>Analytical Chemistry</i> , 2021, 93, 4727-4738.	3.2	41
598	Hypoxia, oxidative stress, and immune evasion: a trinity of the trichothecenes T-2 toxin and deoxynivalenol (DON). <i>Archives of Toxicology</i> , 2021, 95, 1899-1915.	1.9	42
599	Small Extracellular Vesicles: A Novel Avenue for Cancer Management. <i>Frontiers in Oncology</i> , 2021, 11, 638357.	1.3	34
600	Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology. <i>Frontiers in Pharmacology</i> , 2021, 12, 671298.	1.6	16
601	Exosomal Non-coding RNAs-Mediated Crosstalk in the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 646864.	1.8	26
602	Exosomes: Powerful weapon for cancer nano-immunoengineering. <i>Biochemical Pharmacology</i> , 2021, 186, 114487.	2.0	20

#	ARTICLE	IF	CITATIONS
603	Urinary extracellular vesicles: a rising star in bladder cancer management. <i>Translational Andrology and Urology</i> , 2021, 10, 1878-1889.	0.6	12
604	Overview of Subcutaneous Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 2063.	1.7	0
605	The role and potential application of extracellular vesicles in liver cancer. <i>Science China Life Sciences</i> , 2021, 64, 1281-1294.	2.3	10
606	Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 85, 246-252.	4.3	38
607	Towards microfluidic-based exosome isolation and detection for tumor therapy. <i>Nano Today</i> , 2021, 37, 101066.	6.2	112
608	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
609	Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2100049.	2.1	20
610	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 7830.	1.6	50
611	Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. <i>Future Oncology</i> , 2021, 17, 1553-1569.	1.1	9
612	Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T cells and tumour cells. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12075.	5.5	33
613	Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. <i>Journal of Controlled Release</i> , 2021, 332, 109-126.	4.8	33
614	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. <i>Journal of Nanobiotechnology</i> , 2021, 19, 102.	4.2	27
615	Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 665133.	2.2	41
616	PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. <i>Genome Biology</i> , 2021, 22, 104.	3.8	42
617	Ciliary extracellular vesicles are distinct from the cytosolic extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12086.	5.5	16
618	Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2041.	1.7	9
619	Co-Isolation of Cytokines and Exosomes: Implications for Immunomodulation Studies. <i>Frontiers in Immunology</i> , 2021, 12, 638111.	2.2	13
621	Emerging Role of Exosomes in Tuberculosis: From Immunity Regulations to Vaccine and Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 628973.	2.2	17

#	ARTICLE	IF	CITATIONS
622	Single-Cell Immunoblotting based on a Photoclick Hydrogel Enables High-Throughput Screening and Accurate Profiling of Exogenous Gene Expression. <i>Advanced Materials</i> , 2021, 33, e2101108.	11.1	6
623	Investigating the effects of IDO1, PTGS2, and TGF- $\beta$ 1 overexpression on immunomodulatory properties of hTERT-MSCs and their extracellular vesicles. <i>Scientific Reports</i> , 2021, 11, 7825.	1.6	11
624	Extracellular Vesicle Mediated Tumor-Stromal Crosstalk Within an Engineered Lung Cancer Model. <i>Frontiers in Oncology</i> , 2021, 11, 654922.	1.3	8
625	Role of circular RNAs in colorectal tumor microenvironment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111351.	2.5	10
626	Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5497.	1.8	55
627	Extracellular vesicle-transferred long noncoding RNAs in bladder cancer. <i>Clinica Chimica Acta</i> , 2021, 516, 34-45.	0.5	4
628	Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. <i>EBioMedicine</i> , 2021, 67, 103365.	2.7	57
629	The role of exosomal PD-L1 in tumor immunotherapy. <i>Translational Oncology</i> , 2021, 14, 101047.	1.7	31
630	Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1583-1595.	1.5	38
631	Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer. <i>Oncology Letters</i> , 2021, 22, 540.	0.8	8
633	Engineering of Extracellular Vesicles Based on Payload Changes for Tissue Regeneration. <i>Tissue Engineering and Regenerative Medicine</i> , 2021, 18, 485-497.	1.6	9
634	Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5383.	1.8	10
635	The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 189.	7.1	26
636	Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence. <i>Diagnostics</i> , 2021, 11, 917.	1.3	13
637	Advances in Biological Function and Clinical Application of Small Extracellular Vesicle Membrane Proteins. <i>Frontiers in Oncology</i> , 2021, 11, 675940.	1.3	19
638	TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 665265.	1.8	6
639	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. <i>Cancers</i> , 2021, 13, 2630.	1.7	3
640	Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. <i>EMBO Reports</i> , 2021, 22, e50922.	2.0	20

#	ARTICLE	IF	CITATIONS
641	5-aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model. <i>Cancer Science</i> , 2021, 112, 2652-2663.	1.7	6
642	Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 2106-2149.	2.6	95
643	uPAR <sup>+</sup> extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. , 2021, 9, e002372.		23
645	The Role of MRPL23 Antisense RNA 1 (MRPL23-AS1) in the Pre-Metastatic Microenvironment of Malignancy During the Process of Epithelial-Mesenchymal Transition. <i>Journal of Biomaterials and Tissue Engineering</i> , 2021, 11, 864-871.	0.0	0
646	Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12109.	5.5	90
647	Extracellular vesicles: Their emerging roles in the pathogenesis of respiratory diseases. <i>Respiratory Investigation</i> , 2021, 59, 302-311.	0.9	17
648	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBio-SIC-SIF Italian Scientific Societies. <i>ESMO Open</i> , 2021, 6, 100164.	2.0	69
649	Extracellular vesicles in neuroinflammation: Pathogenesis, diagnosis, and therapy. <i>Molecular Therapy</i> , 2021, 29, 1946-1957.	3.7	30
650	Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma. <i>Scientific Reports</i> , 2021, 11, 11743.	1.6	24
651	The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells. <i>Molecular Cancer</i> , 2021, 20, 83.	7.9	47
652	Expanding the codes: The development of density-encoded hydrogel microcarriers for suspension arrays. <i>Biosensors and Bioelectronics</i> , 2021, 181, 113133.	5.3	5
653	Plasma Extracellular Vesicles Enhance HIV-1 Infection of Activated CD4 <sup>+</sup> T Cells and Promote the Activation of Latently Infected J-Lat10.6 Cells via miR-139-5p Transfer. <i>Frontiers in Immunology</i> , 2021, 12, 697604.	2.2	14
654	Interaction of long non-coding RNAs and circular RNAs with microRNAs for the regulation of immunological responses in human cancers. <i>Seminars in Cell and Developmental Biology</i> , 2022, 124, 63-71.	2.3	15
655	Cell-Secreted Vesicles: Novel Opportunities in Cancer Diagnosis, Monitoring and Treatment. <i>Diagnostics</i> , 2021, 11, 1118.	1.3	5
656	Ultrasensitive detection of mRNA in extracellular vesicles using DNA tetrahedron-based thermophoretic assay. <i>Nano Today</i> , 2021, 38, 101203.	6.2	47
657	PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2441-2451.	1.3	19
658	GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSF1/AhR/ARNT signaling axis and extracellular exosome secretion. <i>Oncogene</i> , 2021, 40, 4307-4323.	2.6	14
659	Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1575-1590.	1.4	7

#	ARTICLE	IF	CITATIONS
660	Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 2783.	1.7	8
661	Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. <i>Biomaterials</i> , 2021, 273, 120784.	5.7	140
662	The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. <i>Molecular Therapy</i> , 2021, 29, 1958-1969.	3.7	41
663	Extracellular vesicle and particle-mediated communication shapes innate and adaptive immune responses. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	47
664	Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6234.	1.8	38
665	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2937-2954.	1.3	19
667	Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. <i>Nature Cell Biology</i> , 2021, 23, 631-641.	4.6	213
668	Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis. <i>PLoS ONE</i> , 2021, 16, e0252577.	1.1	10
669	Dissecting Early Relapse in Liver Cancer, One Cell at a Time. <i>Hepatology</i> , 2021, 74, 2891-2893.	3.6	0
670	Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. <i>Cancers</i> , 2021, 13, 3034.	1.7	56
671	Tumor innervation: peripheral nerves take control of the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	79
672	Lipid membrane-based therapeutics and diagnostics. <i>Archives of Biochemistry and Biophysics</i> , 2021, 704, 108858.	1.4	4
673	Extracellular Vesicles and Pancreatic Cancer: Insights on the Roles of miRNA, lncRNA, and Protein Cargos in Cancer Progression. <i>Cells</i> , 2021, 10, 1361.	1.8	17
674	Cancer immunotherapy: it's time to better predict patients' response. <i>British Journal of Cancer</i> , 2021, 125, 927-938.	2.9	63
675	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
676	Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 184.	3.5	204
677	Cross-talks in colon cancer between RAGE/AGEs axis and inflammation/immunotherapy. <i>Oncotarget</i> , 2021, 12, 1281-1295.	0.8	6
678	USP22 deficiency in melanoma mediates resistance to T cells through IFN- $\gamma$ -JAK1-STAT1 signal axis. <i>Molecular Therapy</i> , 2021, 29, 2108-2120.	3.7	11

#	ARTICLE	IF	CITATIONS
679	Nanotraps for the containment and clearance of SARS-CoV-2. <i>Matter</i> , 2021, 4, 2059-2082.	5.0	38
680	Exosomes in the lung cancer microenvironment: biological functions and potential use as clinical biomarkers. <i>Cancer Cell International</i> , 2021, 21, 333.	1.8	10
682	Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. <i>Cancers</i> , 2021, 13, 2777.	1.7	18
683	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 961-978.	0.9	4
684	Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 252-278.	6.6	55
685	The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3040.	1.7	5
686	CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 698503.	1.8	4
687	Adipose Tissue-Derived Extracellular Vesicles and the Tumor Microenvironment: Revisiting the Hallmarks of Cancer. <i>Cancers</i> , 2021, 13, 3328.	1.7	17
688	Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 693321.	1.3	16
689	Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate with COVID-19 disease severity. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12117.	5.5	63
690	PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8 <sup>+</sup> T cell exhaustion during metastasis. <i>Cancer Science</i> , 2021, 112, 3437-3454.	1.7	33
691	Emerging Role of Extracellular Vesicles in Prostate Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	5
692	Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-specific Glycosylation. <i>Angewandte Chemie</i> , 2021, 133, 18259-18263.	1.6	9
693	Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 661-674.	2.0	8
694	Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. <i>Molecular Therapy</i> , 2021, 29, 2321-2334.	3.7	48
695	Prostasin regulates PD-L1 expression in human lung cancer cells. <i>Bioscience Reports</i> , 2021, 41, .	1.1	2
696	Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy. <i>Bioactive Materials</i> , 2022, 9, 251-265.	8.6	30
697	Extracellular vesicles in cancer diagnostics and therapeutics. , 2021, 223, 107806.		42

#	ARTICLE	IF	CITATIONS
698	Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2022, 11, e2100650.	3.9	27
699	Identification of plexin D1 on circulating extracellular vesicles as a potential biomarker of polymyositis and dermatomyositis. <i>Rheumatology</i> , 2022, 61, 1669-1679.	0.9	4
700	Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3385-3400.	1.3	5
701	The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. <i>Cell Communication and Signaling</i> , 2021, 19, 76.	2.7	14
702	Exosomes as New Biomarkers and Drug Delivery Tools for the Prevention and Treatment of Various Diseases: Current Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7763.	1.8	22
703	The multifaceted involvement of exosomes in tumor progression: Induction and inhibition. <i>MedComm</i> , 2021, 2, 297-314.	3.1	10
704	Role and mechanism of neural stem cells of the subventricular zone in glioblastoma. <i>World Journal of Stem Cells</i> , 2021, 13, 877-893.	1.3	23
705	Extracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applications. <i>Cancers</i> , 2021, 13, 3324.	1.7	13
706	The role of exosomes in lung cancer metastasis and clinical applications: an updated review. <i>Journal of Translational Medicine</i> , 2021, 19, 312.	1.8	32
707	Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-specific Glycosylation. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 18111-18115.	7.2	66
708	Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease. <i>Nature Communications</i> , 2021, 12, 4548.	5.8	42
709	A Small Vimentin-Binding Molecule Blocks Cancer Exosome Release and Reduces Cancer Cell Mobility. <i>Frontiers in Pharmacology</i> , 2021, 12, 627394.	1.6	13
710	Retinoblastoma cell-derived exosomes promote angiogenesis of human vesicle endothelial cells through microRNA-92a-3p. <i>Cell Death and Disease</i> , 2021, 12, 695.	2.7	38
711	Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles. <i>Neuro-Oncology</i> , 2022, 24, 197-209.	0.6	21
712	Spinal Cord Repair: From Cells and Tissue Engineering to Extracellular Vesicles. <i>Cells</i> , 2021, 10, 1872.	1.8	32
713	Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours. <i>Current Pharmaceutical Design</i> , 2021, 27, 4515-4529.	0.9	0
714	Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression. <i>Melanoma Research</i> , 2021, 31, 472-475.	0.6	4
715	Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. <i>Drug Discovery Today</i> , 2021, 26, 1656-1668.	3.2	21



#	ARTICLE	IF	CITATIONS
716	Current Applications and Discoveries Related to the Membrane Components of Circulating Tumor Cells and Extracellular Vesicles. <i>Cells</i> , 2021, 10, 2221.	1.8	5
717	THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. , 2021, 9, e002443.		16
718	Extracellular Vesicles Secreted by Tumor Cells Promote the Generation of Suppressive Monocytes. <i>ImmunoHorizons</i> , 2021, 5, 647-658.	0.8	9
719	The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients. <i>Cancers</i> , 2021, 13, 4157.	1.7	17
720	Tumor-Derived Extracellular Vesicles: Their Role in Immune Cells and Immunotherapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5395-5409.	3.3	25
721	Tumor-Derived Extracellular Vesicles: Modulation of Cellular Functional Dynamics in Tumor Microenvironment and Its Clinical Implications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 737449.	1.8	7
722	Prognostic significance of programmed cell deathâ€”ligand 1 expression on circulating tumor cells in various cancers: A systematic review and metaâ€”analysis. <i>Cancer Medicine</i> , 2021, 10, 7021-7039.	1.3	13
723	Ultrasensitive detection of tumor-specific exosomal proteins by a Single Microbead-based Aptasensor coupled with Terminal deoxynucleotidyl transferase-initiated DNA amplification (SMAT). <i>Sensors and Actuators B: Chemical</i> , 2021, 341, 130034.	4.0	3
724	Protein detection in blood with single-molecule imaging. <i>Science Advances</i> , 2021, 7, .	4.7	15
725	Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 710110.	2.2	4
726	The roles of small extracellular vesicles in lung cancer: Molecular pathology, mechanisms, diagnostics, and therapeutics. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188539.	3.3	14
727	Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113833.	6.6	15
728	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	12.8	150
729	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
730	LncRNA nuclearâ€”enriched abundant transcript 1 shuttled by prostate cancer cellsâ€”secreted exosomes initiates osteoblastic phenotypes in the bone metastatic microenvironment via miRâ€”205â€”p/runtâ€”related transcription factor 2/splicing factor prolineâ€”and glutamineâ€”rich/polypyrimidine tractâ€”binding protein 2 axis. <i>Clinical and Translational Medicine</i> , 2021, 11, e493.	1.7	35
731	Tumor-derived exosomes: Nanovesicles made by cancer cells to promote cancer metastasis. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2136-2149.	5.7	35
732	The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review. <i>Journal of Thoracic Disease</i> , 2021, 13, 5093-5103.	0.6	4
733	Matrix-assisted laser desorption ionization mass spectrometry profiling of plasma exosomes evaluates osteosarcoma metastasis. <i>IScience</i> , 2021, 24, 102906.	1.9	20

#	ARTICLE	IF	CITATIONS
734	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	1.3	1
735	PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain. <i>Nature Communications</i> , 2021, 12, 5106.	5.8	38
736	Methylseleninic acid overcomes programmed death ligand 1-mediated resistance of prostate cancer and lung cancer. <i>Molecular Carcinogenesis</i> , 2021, 60, 746-757.	1.3	9
737	Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9414.	1.8	46
738	Small Extracellular Vesicles and Metastasis—Blame the Messenger. <i>Cancers</i> , 2021, 13, 4380.	1.7	11
739	Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses. <i>Gastroenterology</i> , 2021, 161, 560-574.e11.	0.6	47
740	Tumor extracellular vesicles drive metastasis (it's a long way from home). <i>FASEB BioAdvances</i> , 2021, 3, 930-943.	1.3	19
741	Implications and pitfalls for cancer diagnostics exploiting extracellular vesicles. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113819.	6.6	23
742	Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. <i>Cancers</i> , 2021, 13, 4280.	1.7	16
743	Exosomes in Lung Cancer: Actors and Heralds of Tumor Development. <i>Cancers</i> , 2021, 13, 4330.	1.7	13
744	Intercellular communication through extracellular vesicles in cancer and evolutionary biology. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 80-87.	1.4	6
745	A Prehepatectomy Circulating Exosomal microRNA Signature Predicts the Prognosis and Adjuvant Chemotherapeutic Benefits in Colorectal Liver Metastasis. <i>Cancers</i> , 2021, 13, 4258.	1.7	2
746	The Yin and Yang of exosome isolation methods: conventional practice, microfluidics, and commercial kits. <i>Biotechnology Advances</i> , 2022, 54, 107814.	6.0	77
747	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021, 13, 1053-1065.	1.0	16
748	Non-cytoplasmic PD-L1: An atypical target for cancer. <i>Pharmacological Research</i> , 2021, 170, 105741.	3.1	19
749	Aggosome—Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 718589.	1.3	8
750	The power of imaging to understand extracellular vesicle biology in vivo. <i>Nature Methods</i> , 2021, 18, 1013-1026.	9.0	163
751	Emerging nanomedicine-based therapeutics for hematogenous metastatic cascade inhibition: Interfering with the crosstalk between "seed and soil". <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2286-2305.	5.7	8

#	ARTICLE	IF	CITATIONS
752	Advanced Nanotechnologies for Extracellular Vesicle-Based Liquid Biopsy. <i>Advanced Science</i> , 2021, 8, e2102789.	5.6	46
753	Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 651634.	2.2	47
754	The Role of Melanoma Cell-Derived Exosomes (MTEX) and Photodynamic Therapy (PDT) within a Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9726.	1.8	21
755	Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. <i>Cancers</i> , 2021, 13, 4537.	1.7	20
756	Extracellular acidity in tumor tissue upregulates programmed cell death ligand 1 expression on tumor cells via proton-sensing G protein-coupled receptors. <i>International Journal of Cancer</i> , 2021, 149, 2116-2124.	2.3	12
757	Exosomes and organ-specific metastasis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 133-147.	1.8	28
758	The effects of tumor-derived exosomes on T cell function and efficacy of cancer immunotherapy. <i>Immunomedicine</i> , 2021, 1, e1029.	0.7	3
759	Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology. <i>Seminars in Cancer Biology</i> , 2021, 74, 79-91.	4.3	65
760	Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. <i>Cell Metabolism</i> , 2021, 33, 2040-2058.e10.	7.2	200
761	Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications. <i>Cancers</i> , 2021, 13, 4604.	1.7	10
762	Extracellular vesicles in the tumor immune microenvironment. <i>Cancer Letters</i> , 2021, 516, 48-56.	3.2	25
763	Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. <i>Science Immunology</i> , 2021, 6, eabg3551.	5.6	85
764	Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. <i>Biomaterials</i> , 2021, 276, 121058.	5.7	13
765	Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead. <i>Journal of Personalized Medicine</i> , 2021, 11, 971.	1.1	5
766	Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 734720.	1.8	75
767	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. <i>Journal of Cellular Physiology</i> , 2022, 237, 346-372.	2.0	13
768	Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy. <i>Acta Biomaterialia</i> , 2021, 136, 473-484.	4.1	26
769	Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling. <i>ACS Sensors</i> , 2021, 6, 3308-3319.	4.0	35

#	ARTICLE	IF	CITATIONS
770	Extracellular Vesicles (Exosomes) as Immunosuppressive Mediating Variables in Tumor and Chronic Inflammatory Microenvironments. <i>Cells</i> , 2021, 10, 2533.	1.8	8
771	A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis. <i>Nature Communications</i> , 2021, 12, 5733.	5.8	95
772	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 716844.	1.3	12
773	The biology, function, and applications of exosomes in cancer. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2783-2797.	5.7	209
774	The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1041-1053.	5.7	27
775	The Key Role of Exosomes on the Pre-metastatic Niche Formation in Tumors. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 703640.	1.6	38
776	Harnessing EV communication to restore antitumor immunity. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113838.	6.6	7
777	Nanovaccine: an emerging strategy. <i>Expert Review of Vaccines</i> , 2021, 20, 1273-1290.	2.0	50
778	Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response. <i>Journal of Translational Medicine</i> , 2021, 19, 381.	1.8	14
779	PD-L1 regulation revisited: impact on immunotherapeutic strategies. <i>Trends in Molecular Medicine</i> , 2021, 27, 868-881.	3.5	30
780	Serum exosomal miRNA from endometriosis patients correlates with disease severity. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 117-127.	0.8	20
781	Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 837-846.	3.8	45
782	Extracellular Vesicle (EV) biohybrid systems for cancer therapy: Recent advances and future perspectives. <i>Seminars in Cancer Biology</i> , 2021, 74, 45-61.	4.3	19
783	Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. <i>Seminars in Cancer Biology</i> , 2021, 74, 24-44.	4.3	34
784	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	3.4	13
785	tiRNA signaling via stress-regulated vesicle transfer in the hematopoietic niche. <i>Cell Stem Cell</i> , 2021, 28, 2090-2103.e9.	5.2	20
786	Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression. <i>Cancer Letters</i> , 2021, 523, 43-56.	3.2	23
787	Harnessing the therapeutic potential of extracellular vesicles for cancer treatment. <i>Seminars in Cancer Biology</i> , 2021, 74, 92-104.	4.3	9

#	ARTICLE	IF	CITATIONS
788	The Immunomodulation Potential of Exosomes in Tumor Microenvironment. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	15
789	Deciphering Repertoire of B16 Melanoma Reactive TCRs by Immunization, In Vitro Restimulation and Sequencing of IFN $\gamma$ -Secreting T Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9859.	1.8	1
790	Microparticles and PD1 interplay added a prognostic impact in treatment outcomes of patients with multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 17681.	1.6	1
791	Extracellular vesicles in anti-tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 64-79.	4.3	21
792	Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9714.	1.8	20
793	Refining patient selection for breast cancer immunotherapy: beyond PD-L1. <i>ESMO Open</i> , 2021, 6, 100257.	2.0	13
794	Plasma kallikrein predicts primary graft dysfunction after heart transplant. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1199-1211.	0.3	11
795	Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. , 2021, 9, e003148.		18
796	Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 263-280.	1.6	11
797	Small extracellular vesicle-mediated bidirectional crosstalk between neutrophils and tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2021, 61, 16-26.	3.2	18
798	Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. <i>Surgery Open Science</i> , 2021, 6, 10-14.	0.5	4
799	Metabolism and function of polyamines in cancer progression. <i>Cancer Letters</i> , 2021, 519, 91-104.	3.2	52
800	Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis. <i>Molecular Therapy</i> , 2022, 30, 606-620.	3.7	6
801	Exosomes synergized with PIONs@E6 enhance their immunity against hepatocellular carcinoma via promoting M1 macrophages polarization. <i>International Immunopharmacology</i> , 2021, 99, 107960.	1.7	19
802	Extracellular vesicles in acute respiratory distress syndrome: Recent developments from bench to bedside. <i>International Immunopharmacology</i> , 2021, 100, 108118.	1.7	7
803	Small extracellular vesicles in cancer. <i>Bioactive Materials</i> , 2021, 6, 3705-3743.	8.6	61
804	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. <i>Cancer Letters</i> , 2021, 521, 109-118.	3.2	12
805	New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188624.	3.3	29

#	ARTICLE	IF	CITATIONS
806	DNase I-assisted 2-oxo-methyl molecular beacon for amplified detection of tumor exosomal microRNA-21. <i>Talanta</i> , 2021, 235, 122727.	2.9	4
807	Extracellular vesicles, tumor growth, and the metastatic process. , 2022, , 275-284.		0
808	Postlymphadenectomy Analysis of Exosomes from Lymphatic Exudate/Exudative Seroma of Melanoma Patients. <i>Methods in Molecular Biology</i> , 2021, 2265, 345-359.	0.4	0
809	Emerging role of exosomes and exosomal microRNA in cancer: pathophysiology and clinical potential. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 637-648.	1.2	26
810	Recent advances of emerging microfluidic chips for exosome mediated cancer diagnosis. <i>Smart Materials in Medicine</i> , 2021, 2, 158-171.	3.7	13
811	Single microbead-based fluorescent aptasensor (SMFA) for direct isolation and <i>in situ</i> quantification of exosomes from plasma. <i>Analyst</i> , 2021, 146, 3346-3351.	1.7	4
812	Immunoaffinity-Based Isolation of Melanoma Cell-Derived and T Cell-Derived Exosomes from Plasma of Melanoma Patients. <i>Methods in Molecular Biology</i> , 2021, 2265, 305-321.	0.4	16
813	A Protocol for Isolation, Purification, Characterization, and Functional Dissection of Exosomes. <i>Methods in Molecular Biology</i> , 2021, 2261, 105-149.	0.4	33
814	The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 602493.	1.8	31
815	An Immunocapture-Based Assay for Detecting Multiple Antigens in Melanoma-Derived Extracellular Vesicles. <i>Methods in Molecular Biology</i> , 2021, 2265, 323-344.	0.4	9
816	A light-up fluorescence resonance energy transfer magnetic aptamer-sensor for ultra-sensitive lung cancer exosome detection. <i>Journal of Materials Chemistry B</i> , 2021, 9, 2483-2493.	2.9	45
817	Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. <i>Molecular Cancer</i> , 2021, 20, 17.	7.9	67
818	Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer. <i>Cell Transplantation</i> , 2021, 30, 096368972096917.	1.2	9
819	Precise selection of aptamers targeting PD-L1 positive small extracellular vesicles on magnetic chips. <i>Chemical Communications</i> , 2021, 57, 3555-3558.	2.2	7
820	EV PD-L1 Contributes to Immunosuppressive CD8 <sup>+</sup> T Cells in Peripheral Blood of Pediatric Wilms Tumor. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110412.	0.8	3
822	Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. <i>Theranostics</i> , 2021, 11, 8185-8196.	4.6	105
823	Exosomes in Immune Regulation. <i>Non-coding RNA</i> , 2021, 7, 4.	1.3	23
824	Microfluidic-Based Exosome Analysis for Liquid Biopsy. <i>Small Methods</i> , 2021, 5, e2001131.	4.6	81

#	ARTICLE	IF	CITATIONS
825	Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110194.	0.8	8
826	Extracellular vesicle-mediated crosstalk between melanoma and the immune system: Impact on tumor progression and therapy response. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1101-1115.	1.5	13
827	Secretome of Activated Fibroblasts Induced by Exosomes for the Discovery of Biomarkers in Nonâ€Small Cell Lung Cancer. <i>Small</i> , 2021, 17, e2004750.	5.2	18
828	Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402.		1
829	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 251-279.	0.2	15
830	Checkpoints Under Traffic Control: From and to Organelles. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 431-453.	0.8	8
831	Exosome and Secretion: Action On?. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 455-483.	0.8	13
832	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 33-59.	0.8	232
833	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 143-166.	0.8	3
834	Actin remodeling and vesicular trafficking at the tumor cell side of the immunological synapse direct evasion from cytotoxic lymphocytes. <i>International Review of Cell and Molecular Biology</i> , 2020, 356, 99-130.	1.6	9
835	A hydrophilic magnetic MOF for the consecutive enrichment of exosomes and exosomal phosphopeptides. <i>Chemical Communications</i> , 2020, 56, 13999-14002.	2.2	47
836	Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma. <i>Bioscience Reports</i> , 2020, 40, .	1.1	26
840	Exosomal <sc>miRâ€180â€3p</sc> inhibits proliferation and metastasis of nonâ€small cell lung cancer by downregulating <sc>FOXP4</sc>. <i>Thoracic Cancer</i> , 2021, 12, 372-381.	0.8	21
841	PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. <i>Journal of Clinical Investigation</i> , 2020, 130, 3603-3620.	3.9	90
842	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	15
843	The role of extracellular vesicles in prostate cancer with clinical applications. <i>Endocrine-Related Cancer</i> , 2020, 27, R133-R144.	1.6	12
844	The Roles of MicroRNAs and Extracellular Vesicles in the Pathogenesis of Idiopathic Pulmonary Fibrosis and Acute Respiratory Distress Syndrome. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 251, 313-326.	0.5	6
845	Circ-0001068 is a novel biomarker for ovarian cancer and inducer of PD1 expression in T cells. <i>Aging</i> , 2020, 12, 19095-19106.	1.4	36

#	ARTICLE	IF	CITATIONS
846	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
847	The role of exosomes in tumor immunity. <i>Annals of Translational Medicine</i> , 2018, 6, S116-S116.	0.7	9
848	Exosomes as critical mediators of cell-to-cell communication in cancer pathogenesis and their potential clinical application. <i>Translational Cancer Research</i> , 2019, 8, 298-311.	0.4	32
849	RAB27A-mediated melanoma exosomes: promoters of invasion and metastasis. <i>Translational Cancer Research</i> , 2019, 8, 732-735.	0.4	4
850	Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression. <i>Current Pharmaceutical Design</i> , 2019, 25, 1980-2006.	0.9	11
851	Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. <i>Journal of Medical Biochemistry</i> , 2019, 38, 332-341.	0.7	21
852	Innate extracellular vesicles from melanoma patients suppress $\beta$ -catenin in tumor cells by miRNA-34a. <i>Life Science Alliance</i> , 2019, 2, e201800205.	1.3	22
853	The Role of Tumor-Derived Vesicles in the Regulation of Antitumor Immunity. <i>Acta Naturae</i> , 2019, 11, 33-41.	1.7	18
854	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
855	Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases. <i>Cancers</i> , 2021, 13, 84.	1.7	36
856	Extracellular Vesicles for Cancer Therapy: Impact of Host Immune Response. <i>Cells</i> , 2020, 9, 224.	1.8	10
858	Exosomal circular RNA sorting mechanisms and their function in promoting or inhibiting cancer (Review). <i>Oncology Letters</i> , 2020, 19, 3369-3380.	0.8	30
859	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation (Review). <i>Oncology Reports</i> , 2020, 44, 424-437.	1.2	18
860	Defining lung cancer stem cells exosomal payload of miRNAs in clinical perspective. <i>World Journal of Stem Cells</i> , 2020, 12, 406-421.	1.3	16
861	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. <i>Theranostics</i> , 2020, 10, 2309-2326.	4.6	124
862	Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. <i>ELife</i> , 2019, 8, .	2.8	44
863	The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. <i>ELife</i> , 2020, 9, .	2.8	168
864	Exosomal cargoes in OSCC: current findings and potential functions. <i>PeerJ</i> , 2020, 8, e10062.	0.9	16



#	ARTICLE	IF	CITATIONS
865	Liquid Biopsy. UNIPA Springer Series, 2021, , 99-122.	0.1	0
866	The Tumour Microenvironment and Circulating Tumour Cells: A Partnership Driving Metastasis and Glycan-Based Opportunities for Cancer Control. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 1-33.	0.8	2
867	The Roles of Extracellular Vesicles in Malignant Melanoma. <i>Cells</i> , 2021, 10, 2740.	1.8	16
868	Role of Extracellular Vesicles in Cell Death and Inflammation. <i>Cells</i> , 2021, 10, 2663.	1.8	33
869	Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment. , 2021, 9, e003217.		29
870	Tumor-Derived Extracellular Vesicles: A Means of Co-opting Macrophage Polarization in the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 746432.	1.8	14
871	PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 5200.	1.7	6
872	Converting extracellular vesicles into nanomedicine: loading and unloading of cargo. <i>Materials Today Nano</i> , 2021, 16, 100148.	2.3	19
873	Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients. <i>British Journal of Cancer</i> , 2021, 125, 1677-1686.	2.9	24
874	Stem cells from exfoliated deciduous teeth transplantation ameliorates Sjögren's syndrome by secreting soluble PD-L1. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1043-1055.	1.5	10
875	Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?. <i>Journal of NeuroImmune Pharmacology</i> , 2021, , 1.	2.1	2
876	Evaluation of EpCAM-specific exosomal lncRNAs as potential diagnostic biomarkers for lung cancer using droplet digital PCR. <i>Journal of Molecular Medicine</i> , 2022, 100, 87-100.	1.7	15
877	Extracellular Vesicles Regulated by Viruses and Antiviral Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 722020.	1.8	15
878	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760211.	1.8	9
880	Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16020-16045.	2.9	16
881	Breast Cancer Stem Cell-Derived ANXA6-Containing Exosomes Sustain Paclitaxel Resistance and Cancer Aggressiveness in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 718721.	1.8	14
882	Exosomes: Emerging Cell-Free Based Therapeutics in Dermatologic Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 736022.	1.8	12
883	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588

#	ARTICLE	IF	CITATIONS
884	pH-Mediated Clustering of Exosomes: Breaking Through the Size Limit of Exosome Analysis in Conventional Flow Cytometry. <i>Nano Letters</i> , 2021, 21, 8817-8823.	4.5	28
885	Non-immune Cell Components in the Gastrointestinal Tumor Microenvironment Influencing Tumor Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 729941.	1.8	4
886	Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 738373.	1.8	15
887	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
888	Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. <i>Cell Communication and Signaling</i> , 2021, 19, 104.	2.7	78
889	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 326.	3.5	19
890	Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications. , 2022, 233, 108025.		50
893	Natural Products with Activity against Lung Cancer: A Review Focusing on the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10827.	1.8	30
894	Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/ miR-142-5p/ PD-L1 axis. <i>Molecular Immunology</i> , 2021, 140, 47-58.	1.0	25
895	Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44.		0
896	Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S22-S22.	0.7	2
897	Extracellular vesicles as gold mine for new diagnostic and therapeutic approaches in medicine. <i>Trillium Extracellular Vesicles</i> , 2019, 1, 10-17.	0.1	1
899	La biopsia líquida en el manejo del cáncer: una nueva herramienta revolucionaria de la medicina de precisión, aún con limitaciones. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
900	Extracellular Vesicles and Their Roles in Cancer Progression. <i>Methods in Molecular Biology</i> , 2021, 2174, 143-170.	0.4	82
901	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
902	Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5124.	1.0	10
903	Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound. <i>Gynecologic Oncology</i> , 2021, , .	0.6	3
904	Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?. <i>Metabolites</i> , 2021, 11, 756.	1.3	10

#	ARTICLE	IF	CITATIONS
905	The Microenvironment of Tongue Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 49-78.	0.8	1
906	Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1995166.	2.1	12
907	Advancement of clinical therapeutic research on glioma: A narrative review. <i>Glioma (Mumbai, India)</i> , 2020, 3, 119.	0.0	1
909	The roles of exosomal immune checkpoint proteins in tumors. <i>Military Medical Research</i> , 2021, 8, 56.	1.9	12
910	Phospholipids in small extracellular vesicles: emerging regulators of neurodegenerative diseases and cancer. <i>Cytotherapy</i> , 2021, , .	0.3	5
911	Hallmarks of Exosomes. <i>Future Science OA</i> , 2022, 8, FSO764.	0.9	14
912	Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1549-1567.	2.0	20
913	Exosomes: Promising nanocarrier for cancer therapy. <i>Nano Select</i> , 0, , .	1.9	3
914	Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies. <i>Frontiers in Immunology</i> , 2021, 12, 772408.	2.2	12
915	VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes. <i>Cancers</i> , 2021, 13, 5559.	1.7	2
916	CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion. <i>Cell Death and Disease</i> , 2021, 12, 1065.	2.7	30
917	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1333-1353.	1.1	9
918	Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection. <i>Advanced Science</i> , 2022, 9, e2102634.	5.6	18
920	BMAL1 induces colorectal cancer metastasis by stimulating exosome secretion. <i>Molecular Biology Reports</i> , 2022, 49, 373-384.	1.0	11
921	An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1501-1513.	1.8	5
925	CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients. <i>Aging</i> , 2020, 12, 21809-21836.	1.4	12
926	Perspective "Escape from destruction: how cancer-derived EVs are protected from phagocytosis. <i>Trillium Extracellular Vesicles</i> , 2020, 2, 60-64.	0.1	2
927	Pancreatic cancer-derived small extracellular vesical Ezrin regulates macrophage polarization and promotes metastasis. <i>American Journal of Cancer Research</i> , 2020, 10, 12-37.	1.4	17

#	ARTICLE	IF	CITATIONS
929	Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type. <i>American Journal of Cancer Research</i> , 2020, 10, 4498-4512.	1.4	6
930	Exosomes in osteosarcoma research and preclinical practice. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 882-897.	0.0	5
931	Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100489.	0.7	2
932	Drug delivery approaches for HuR-targeted therapy for lung cancer. <i>Advanced Drug Delivery Reviews</i> , 2022, 180, 114068.	6.6	7
933	Effect of SMMC-7721-derived exosomes on hepatocytes studied by AFM. , 2021, , .		0
934	Proteomic analysis of human umbilical cord serum exosomes using mass spectrometry and preliminary study of their biological activities in liver cancer cell lines. <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 44.	0.8	0
935	Norcholeic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 711448.	1.3	18
937	<i>In Situ</i> Visualization of PD-L1-Specific Glycosylation on Tissue Sections. <i>Analytical Chemistry</i> , 2021, 93, 15958-15963.	3.2	18
938	Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy. <i>Journal of Cellular Physiology</i> , 2022, 237, 1648-1660.	2.0	10
939	A Compact Surface Plasmon Resonance Biosensor for Sensitive Detection of Exosomal Proteins for Cancer Diagnosis. <i>Methods in Molecular Biology</i> , 2022, 2393, 3-14.	0.4	3
940	Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. <i>ELife</i> , 2021, 10, .	2.8	14
941	Tumor-Associated Exosomes: A Potential Therapeutic Target for Restoring Anti-Tumor T Cell Responses in Human Tumor Microenvironments. <i>Cells</i> , 2021, 10, 3155.	1.8	11
942	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 26-42.	2.0	26
943	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. <i>Cancer Research</i> , 2022, 82, 349-358.	0.4	57
944	The role of exosomal lncRNAs in cancer biology and clinical management. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1669-1673.	3.2	22
945	Antimetastatic defense by CD8+ T cells. <i>Trends in Cancer</i> , 2022, 8, 145-157.	3.8	12
946	GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 397.	7.1	58
947	Extracellular Vesicles for the Diagnosis of Cancers. <i>Small Structures</i> , 2022, 3, 2100096.	6.9	7

#	ARTICLE	IF	CITATIONS
948	Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients. <i>Human Cell</i> , 2021, , 1.	1.2	0
950	Acidic and Hypoxic Microenvironment in Melanoma: Impact of Tumour Exosomes on Disease Progression. <i>Cells</i> , 2021, 10, 3311.	1.8	12
951	Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients. , 2021, 9, A25-A26.		0
952	Tango of dual nanoparticles: Interplays between exosomes and nanomedicine. <i>Bioengineering and Translational Medicine</i> , 2022, 7, e10269.	3.9	6
953	An Exploration of Non-Coding RNAs in Extracellular Vesicles Delivered by Swine Anterior Pituitary. <i>Frontiers in Genetics</i> , 2021, 12, 772753.	1.1	3
954	CMTM6, a potential immunotherapy target. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 47-56.	1.2	7
955	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave. <i>Biomedicines</i> , 2021, 9, 1702.	1.4	11
956	The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target. <i>Cells</i> , 2021, 10, 3247.	1.8	24
957	Cancer stem cells: advances in biology and clinical translation” a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1506, 142-163.	1.8	8
958	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	21
959	Overexpression of PD-L1 in Papillary Carcinoma and Its Association with Clinicopathological Variables. <i>Duzce Universitesi Tip Fakültesi Dergisi</i> , 0, , .	0.3	0
960	Cancer associated-fibroblast-derived exosomes in cancer progression. <i>Molecular Cancer</i> , 2021, 20, 154.	7.9	116
961	Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103565.	2.0	49
962	Extracellular vesicles in pharmacology: Novel approaches in diagnostics and therapy. <i>Pharmacological Research</i> , 2022, 175, 105980.	3.1	8
963	Extracellular Vesicles and Glycosylation. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1325, 137-149.	0.8	6
964	Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression. <i>Tzu Chi Medical Journal</i> , 2022, 34, 1.	0.4	8
965	Recent Advances in Aptamer-Based Liquid Biopsy. <i>ACS Applied Bio Materials</i> , 2022, 5, 1954-1979.	2.3	12
966	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	0

#	ARTICLE	IF	CITATIONS
967	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma. <i>Scientific Reports</i> , 2022, 12, 36.	1.6	7
968	Biomarkers for predicting the efficacy of immune checkpoint inhibitors. <i>Journal of Cancer</i> , 2022, 13, 481-495.	1.2	12
969	An Ultrasensitive Strand Displacement Signal Amplification-Assisted Synchronous Fluorescence Assay for Surface Proteins of Small Extracellular Vesicle Analysis and Cancer Identification. <i>Analytical Chemistry</i> , 2022, 94, 1085-1091.	3.2	23
970	Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. <i>Gut</i> , 2022, 71, 2043-2068.	6.1	53
971	Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 611-620.	2.3	33
972	Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 15.	7.9	38
973	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. <i>Molecular Cancer</i> , 2022, 21, 20.	7.9	55
974	Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers. <i>Cancers</i> , 2022, 14, 288.	1.7	11
975	Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. <i>Medicinal Research Reviews</i> , 2022, 42, 1246-1279.	5.0	38
976	Glioma-targeted multifunctional nanoparticles to co-deliver camptothecin and curcumin for enhanced chemo-immunotherapy. <i>Biomaterials Science</i> , 2022, 10, 1292-1303.	2.6	13
977	Tumor-Derived Exosomes in Tumor-Induced Immune Suppression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1461.	1.8	28
978	The mechanism underlying arsenic-induced PD-L1 upregulation in transformed BEAS-2B cells. <i>Toxicology and Applied Pharmacology</i> , 2022, 435, 115845.	1.3	4
979	Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. <i>Cell Death and Disease</i> , 2022, 13, 64.	2.7	50
980	A simple, rapid and low-cost qPCR assay for evaluating the severity of exosomal PD-L1-mediated T cell exhaustion in blood samples. <i>Chemical Communications</i> , 2022, 58, 831-834.	2.2	2
981	Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy. <i>Journal of the American Chemical Society</i> , 2022, 144, 787-797.	6.6	142
982	Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. <i>Cancers</i> , 2022, 14, 751.	1.7	5
983	Exosomes in cancer immunoediting and immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 193-205.	4.3	21
984	Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. <i>Molecular Cancer</i> , 2022, 21, 19.	7.9	63

#	ARTICLE	IF	CITATIONS
985	Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects. <i>Cells</i> , 2022, 11, 490.	1.8	21
986	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	1.2	1
987	Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2197-2212.	2.0	9
989	Immuno-Engineered Nanodecoys for the Multi-Target Anti-Inflammatory Treatment of Autoimmune Diseases. <i>Advanced Materials</i> , 2022, 34, e2108817.	11.1	49
990	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 809761.	2.2	29
991	Exosomal Proteins and Lipids as Potential Biomarkers for Lung Cancer Diagnosis, Prognosis, and Treatment. <i>Cancers</i> , 2022, 14, 732.	1.7	35
992	The Role of Exosomal Non-Coding RNAs in Colorectal Cancer Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1473.	1.8	18
993	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. <i>Developmental Cell</i> , 2022, 57, 329-343.e7.	3.1	42
994	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. <i>Biomolecules</i> , 2022, 12, 132.	1.8	7
995	Radio Signals from Live Cells: The Coming of Age of In-Cell Solution NMR. <i>Chemical Reviews</i> , 2022, 122, 9267-9306.	23.0	42
996	The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1 blockade agents. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1823-1835.	2.0	9
997	Clinical Translational Potentials of Stem Cell-Derived Extracellular Vesicles in Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 682145.	1.5	5
998	Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma cfDNA, LDH, VEGF, PD-L1, and IFN- $\gamma$ Measurements. <i>Anticancer Research</i> , 2022, 42, 801-810.	0.5	0
999	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 405.	5.8	92
1000	Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. <i>Cell Communication and Signaling</i> , 2022, 20, 14.	2.7	23
1001	PD-L1 in circulating exosomes of Merkel cell carcinoma. <i>Experimental Dermatology</i> , 2022, 31, 869-877.	1.4	6
1002	Self-Blockade of PD-L1 with Bacteria-Derived Outer-Membrane Vesicle for Enhanced Cancer Immunotherapy. <i>Advanced Materials</i> , 2022, 34, e2106307.	11.1	51
1003	Tumor-derived extracellular vesicles: Potential tool for cancer diagnosis, prognosis, and therapy. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 2063-2071.	1.8	12

#	ARTICLE	IF	CITATIONS
1004	Diversity of Extracellular Vesicles (EV) in Plasma of Cancer Patients. <i>Physiology</i> , 0, , .	4.0	0
1005	Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer. <i>Clinical and Experimental Immunology</i> , 2022, 207, 307-317.	1.1	21
1006	Extracellular Vesicles as Biomarkers and Therapeutic Targets in Cancers. <i>Physiology</i> , 0, , .	4.0	1
1007	Myricetin inhibits interferon- $\beta$ -induced PD-L1 and IDO1 expression in lung cancer cells. <i>Biochemical Pharmacology</i> , 2022, 197, 114940.	2.0	20
1008	Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 299-318.	2.0	9
1009	The interweaving relationship between extracellular vesicles and T cells in cancer. <i>Cancer Letters</i> , 2022, 530, 1-7.	3.2	11
1010	Tumor-derived exosomes: immune properties and clinical application in lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 102-113.	0.9	5
1011	Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1. <i>Theranostics</i> , 2022, 12, 1971-1987.	4.6	30
1012	Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 129-146.	0.9	4
1013	Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 287-305.	12.5	155
1014	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
1015	Serum Exosomal lncRNA AC007099.1 Regulates the Expression of Neuropeptide-Related FAP, as a Potential Biomarker for Hepatocarcinogenesis. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	4
1016	Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2022, 86, 1088-1101.	4.3	3
1017	Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2103444.	5.6	102
1018	Regulation of Trafficking Vesicles by Extracellular Matrix Stiffness: Combined Data-Driven and Biophysical Insights. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1019	A modular microfluidic platform for serial enrichment and harvest of pure extracellular vesicles. <i>Analyst, The</i> , 2022, 147, 1117-1127.	1.7	8
1020	Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation. <i>Cancers</i> , 2022, 14, 903.	1.7	15
1021	Roles and Clinical Application of Exosomes in Prostate Cancer. <i>Frontiers in Urology</i> , 2022, 2, .	0.2	3



#	ARTICLE	IF	CITATIONS
1022	Emerging Concepts on the Role of Extracellular Vesicles and Its Cargo Contents in Glioblastoma-Microglial Crosstalk. <i>Molecular Neurobiology</i> , 2022, 59, 2822-2837.	1.9	10
1023	Current Perspectives on the Unique Roles of Exosomes in Drug Resistance of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 99-112.	1.8	12
1024	Exosome Processing and Characterization Approaches for Research and Technology Development. <i>Advanced Science</i> , 2022, 9, e2103222.	5.6	89
1025	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
1026	Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12209.	5.5	18
1027	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 830208.	1.8	13
1028	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2847.	1.8	19
1029	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. , 2022, 10, e004043.		34
1030	Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. <i>Molecular Cancer</i> , 2022, 21, 86.	7.9	72
1031	miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 308-329.	2.0	12
1032	LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. <i>Molecular Cancer</i> , 2022, 21, 75.	7.9	54
1033	Potential Resistance to Antineoplastic Aminated Fullerenes Mediated by M2-Like Monocyte-Derived Exosomes. <i>Frontiers in Oncology</i> , 2022, 12, 779939.	1.3	1
1034	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 827921.	2.2	43
1035	Evaluation of Immunoregulatory Biomarkers on Plasma Small Extracellular Vesicles for Disease Progression and Early Therapeutic Response in Head and Neck Cancer. <i>Cells</i> , 2022, 11, 902.	1.8	9
1036	Tumor-Derived Exosome and Immune Modulation. <i>Physiology</i> , 0, , .	4.0	2
1037	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 253-264.	1.5	20
1038	Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in <i>TP53</i> -deficient B-cell malignancies. <i>Blood</i> , 2022, 139, 3617-3629.	0.6	12
1039	Melanoma and Nanotechnology-Based Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 858185.	1.3	12

#	ARTICLE	IF	CITATIONS
1040	Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 752818.	1.8	15
1041	Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. <i>Oncologist</i> , 2022, 27, 352-362.	1.9	6
1042	Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	13
1043	Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer. <i>Advanced Science</i> , 2022, 9, e2104452.	5.6	20
1044	Exosomes for Regulation of Immune Responses and Immunotherapy. <i>Journal of Nanotheranostics</i> , 2022, 3, 55-85.	1.7	16
1045	Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2022, 14, 1669.	1.7	6
1046	Microglia Polarization: A Novel Target of Exosome for Stroke Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 842320.	1.8	16
1047	IL-3 signalling in the tumour microenvironment shapes the immune response via tumour endothelial cell-derived extracellular vesicles. <i>Pharmacological Research</i> , 2022, 179, 106206.	3.1	11
1048	Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 872531.	1.3	16
1049	Radiation therapy-induced remodeling of the tumor immune microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 737-747.	4.3	30
1050	Platelet Phagocytes for the Hierarchical Amplification of Antitumor Immunity in Response to Self-Generated Immune Signals. <i>Advanced Materials</i> , 2022, 34, e2109517.	11.1	31
1051	IL-6 Promotes Hepatocellular Carcinoma Invasion by Releasing Exosomal miR-133a-3p. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-12.	0.7	2
1052	Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1159-1174.	1.2	6
1053	The RNA-binding protein HuR in human cancer: A friend or foe?. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114179.	6.6	41
1054	Integrated microfluidic system for isolating exosome and analyzing protein marker PD-L1. <i>Biosensors and Bioelectronics</i> , 2022, 204, 113879.	5.3	28
1055	Current methods and emerging approaches for detection of programmed death ligand 1. <i>Biosensors and Bioelectronics</i> , 2022, 208, 114179.	5.3	3
1056	An electrochemical biosensor for PD-L1 positive exosomes based on ultra-thin two-dimensional covalent organic framework nanosheets coupled with CRISPR-Cas12a mediated signal amplification. <i>Sensors and Actuators B: Chemical</i> , 2022, 362, 131813.	4.0	30
1057	An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 421.	7.1	48

#	ARTICLE	IF	CITATIONS
1058	Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. Expert Opinion on Drug Safety, 2022, 21, 599-612.	1.0	1
1059	Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. Advanced Science, 2022, 9, e2103245.	5.6	22
1060	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	21.5	201
1061	Surface Nanosieving Polyether Sulfone Particles with Graphene Oxide Encapsulation for the Negative Isolation toward Extracellular Vesicles. Analytical Chemistry, 2021, 93, 16835-16844.	3.2	5
1062	Hedgehog-inspired magnetic nanoparticles for effectively capturing and detecting exosomes. NPG Asia Materials, 2021, 13, .	3.8	10
1063	The Role of Extracellular Vesicles in the Progression of Tumors towards Metastasis. Physiology, 0, , .	4.0	0
1064	Hypoxia-Induced Intracellular and Extracellular Heat Shock Protein gp96 Increases Paclitaxel-Resistance and Facilitates Immune Evasion in Breast Cancer. Frontiers in Oncology, 2021, 11, 784777.	1.3	15
1065	The Role of Exosomes in Cancer Progression. International Journal of Molecular Sciences, 2022, 23, 8.	1.8	23
1066	Intra- and Extracellular Effector Vesicles From Human T And NK Cells: Same-Same, but Different?. Frontiers in Immunology, 2021, 12, 804895.	2.2	11
1067	Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients. Journal of Extracellular Vesicles, 2021, 10, e12173.	5.5	19
1068	Extracellular Vesicles and Transforming Growth Factor $\beta$ Signaling in Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 849938.	1.8	14
1069	Mesenchymal stem cell-derived exosomal microRNA-182-5p alleviates myocardial ischemia/reperfusion injury by targeting GSDMD in mice. Cell Death Discovery, 2022, 8, 202.	2.0	33
1070	Extracellular Vesicles and Their Emerging Roles as Cellular Messengers in Endocrinology: An Endocrine Society Scientific Statement. Endocrine Reviews, 2022, 43, 441-468.	8.9	40
1071	Untouched isolation enables targeted functional analysis of tumour-cell-derived extracellular vesicles from tumour tissues. Journal of Extracellular Vesicles, 2022, 11, e12214.	5.5	10
1072	Cancer cell's internal and external warriors: Autophagosomes and exosomes. Life Sciences, 2022, 300, 120552.	2.0	3
1073	Irradiated Cell-Derived Exosomes Transmit Essential Molecules Inducing Radiation Therapy Resistance. International Journal of Radiation Oncology Biology Physics, 2022, 113, 192-202.	0.4	5
1074	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. Advanced Drug Delivery Reviews, 2022, 185, 114301.	6.6	28
1075	Bioprobes-regulated precision biosensing of exosomes: From the nanovesicle surface to the inside. Coordination Chemistry Reviews, 2022, 463, 214538.	9.5	14

#	ARTICLE	IF	CITATIONS
1109	Research Progress in the Application of Exosomes in Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 731516.	2.2	10
1110	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. <i>Expert Review of Proteomics</i> , 2022, 19, 115-129.	1.3	3
1111	Research progress in proteasome inhibitor resistance to multiple myeloma. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 900-908.	0.1	1
1113	A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer. <i>Chemical Science</i> , 2022, 13, 5345-5352.	3.7	16
1114	Monitoring of Circulating Exosomal Immuno Checkpoint in Tumor Microenvironment Through Ultrasensitive Aptamer-Functionalized Sers Probes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1115	â·¥ç“‘â€—ç»†èfžâ—â·šæ³;ăŽç™Œç—†æ²»ç——. <i>Scientia Sinica Vitae</i> , 2022, , .	0.1	0
1116	Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis. <i>Oncolmmunology</i> , 2022, 11, 2067944.	2.1	12
1117	Biomimetic approaches for targeting tumor-promoting inflammation. <i>Seminars in Cancer Biology</i> , 2022, 86, 555-567.	4.3	15
1118	Bio-Conjugated Magnetic-Fluorescence Nanoarchitectures for the Capture and Identification of Lung-Tumor-Derived Programmed Cell Death Lighand 1-Positive Exosomes. <i>ACS Omega</i> , 2022, 7, 16035-16042.	1.6	5
1119	The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment. <i>Cells</i> , 2022, 11, 1433.	1.8	17
1120	Exosomes and ferroptosis: roles in tumour regulation and new cancer therapies. <i>PeerJ</i> , 2022, 10, e13238.	0.9	7
1121	Recent progress on microfluidic devices with incorporated 1D nanostructures for enhanced extracellular vesicle (EV) separation. <i>Bio-Design and Manufacturing</i> , 2022, 5, 607-616.	3.9	5
1122	Transfer of IGF2BP3 Through Ara-C-Induced Apoptotic Bodies Promotes Survival of Recipient Cells. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	4
1123	Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5343.	1.8	3
1124	Greek Fire, Poison Arrows, and Scorpion Bombs: How Tumor Cells Defend Against the Siege Weapons of Cytotoxic T Lymphocytes. <i>Frontiers in Immunology</i> , 2022, 13, 894306.	2.2	9
1125	Application of lipid nanovesicle drug delivery system in cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 214.	4.2	24
1126	Macrophage Differentiation and Polarization Regulate the Release of the Immune Checkpoint Protein V-Domain Ig Suppressor of T Cell Activation. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
1127	Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies. <i>Viruses</i> , 2022, 14, 1017.	1.5	11

#	ARTICLE	IF	CITATIONS
1128	Extracellular vesicles: Emerging tools as therapeutic agent carriers. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3822-3842.	5.7	33
1129	Autoimmunity and Cancer—Two Sides of the Same Coin. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	16
1130	Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. <i>Clinical Cancer Research</i> , 2022, 28, 3021-3031.	3.2	32
1131	Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. <i>Clinical and Experimental Immunology</i> , 2022, 208, 316-322.	1.1	13
1132	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. <i>Cancers</i> , 2022, 14, 2408.	1.7	15
1133	CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12218.	5.5	31
1134	Advances in understanding cancer-associated neurogenesis and its implications on the neuroimmune axis in cancer. , 2022, 239, 108199.		5
1135	Immunosuppressive Extracellular Vesicles as a Linking Factor in the Development of Tumor and Endometriotic Lesions in the Gynecologic Tract. <i>Cells</i> , 2022, 11, 1483.	1.8	4
1136	Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles. <i>Biosensors</i> , 2022, 12, 281.	2.3	7
1137	Macrophage-mediated tumor-targeted delivery of engineered <i>Salmonella typhimurium</i> VNP20009 in anti-PD1 therapy against melanoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3952-3971.	5.7	11
1138	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. <i>BMJ Open</i> , 2022, 12, e050112.	0.8	6
1139	Ultrasensitive Single Extracellular Vesicle Detection Using High Throughput Droplet Digital Enzyme-Linked Immunosorbent Assay. <i>Nano Letters</i> , 2022, 22, 4315-4324.	4.5	26
1140	Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. , 2022, 10, e004399.		18
1141	The role of biomarkers in personalized immunotherapy. <i>Biomarker Research</i> , 2022, 10, 32.	2.8	27
1142	Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response. <i>Nanoscale</i> , 2022, 14, 8995-9003.	2.8	14
1143	Targeting type III phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer. <i>Theranostics</i> , 2022, 12, 4386-4398.	4.6	3
1144	Engineered extracellular vesicles as intelligent nanosystems for next-generation nanomedicine. <i>Nanoscale Horizons</i> , 2022, 7, 682-714.	4.1	37
1146	Nasopharyngeal cancer cell-derived exosomal <i>PD-L1</i> inhibits <i>CD8</i> + T cell activity and promotes immune escape. <i>Cancer Science</i> , 2022, 113, 3044-3054.	1.7	20

#	ARTICLE	IF	CITATIONS
1147	Function and therapeutic development of exosomes for cancer therapy. Archives of Pharmacal Research, 2022, 45, 295-308.	2.7	15
1148	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines, 2022, 10, 1181.	1.4	8
1149	Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review. Biomedicines, 2022, 10, 1237.	1.4	7
1150	Extracellular vesicles: from bench to bedside. , 2022, 1, .		3
1151	Exosome Carrier Effects; Resistance to Digestion in Phagolysosomes May Assist Transfers to Targeted Cells; II Transfers of miRNAs Are Better Analyzed via Systems Approach as They Do Not Fit Conventional Reductionist Stoichiometric Concepts. International Journal of Molecular Sciences, 2022, 23, 6192.	1.8	5
1152	Hydrogels for Exosome Delivery in Biomedical Applications. Gels, 2022, 8, 328.	2.1	28
1153	Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. Cancers, 2022, 14, 2626.	1.7	7
1154	Recent applications of immunomodulatory biomaterials for disease immunotherapy. Exploration, 2022, 2, .	5.4	81
1155	Small Extracellular Vesicles: Key Forces Mediating the Development and Metastasis of Colorectal Cancer. Cells, 2022, 11, 1780.	1.8	6
1156	Three-Dimensional Microfluidic Chip for Efficient Capture of Secretory Autophagosomes and Sensitive Detection of Their Surface Proteins. Analytical Chemistry, 2022, 94, 8489-8496.	3.2	5
1157	Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL. Scientific Reports, 2022, 12, .	1.6	2
1158	Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity. International Journal of Radiation Oncology Biology Physics, 2022, 114, 725-737.	0.4	6
1159	Novel Strategy for Optimized Nanocatalytic Tumor Therapy: From an Updated View. Small Science, 2022, 2, .	5.8	10
1160	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with Non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	39
1161	Programmable DNA-Fueled Electrochemical Analysis of Lung Cancer Exosomes. Analytical Chemistry, 2022, 94, 8748-8755.	3.2	22
1162	Proteomic profiling of serum small extracellular vesicles reveals immune signatures of children with pneumonia. Translational Pediatrics, 2022, 11, 891-908.	0.5	4
1163	Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance. Cancer Drug Resistance (Alhambra, Calif ), 2022, 5, 577-94.	0.9	7
1164	Engineering PD-L1 Cellular Nanovesicles Encapsulating Epidermal Growth Factor for Deep Second-Degree Scald Treatment. Journal of Biomedical Nanotechnology, 2022, 18, 898-908.	0.5	2

#	ARTICLE	IF	CITATIONS
1165	Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. <i>Current Oncology</i> , 2022, 29, 4185-4198.	0.9	12
1166	Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1167	Extracellular vesicles in cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 296-309.	4.3	23
1168	Comprehensive insight into endothelial progenitor cell-derived extracellular vesicles as a promising candidate for disease treatment. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	11
1169	Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy. <i>ACS Nano</i> , 2022, 16, 10327-10340.	7.3	51
1170	Nano-Biomaterials for Immunotherapy Applications. , 2022, , 30-48.		0
1171	Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 23-37.	1.4	7
1172	Monitoring of circulating exosomal immune checkpoint in tumor microenvironment through ultrasensitive aptamer-functionalized SERS probes. <i>Biosensors and Bioelectronics: X</i> , 2022, 12, 100177.	0.9	1
1173	Extracellular Vesicles and Resistance to Anticancer Drugs: A Tumor Skeleton Key for Unhinging Chemotherapies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1174	Small extracellular vesicles derived from PD-L1-modified mesenchymal stem cell promote Tregs differentiation and prolong allograft survival. <i>Cell and Tissue Research</i> , 2022, 389, 465-481.	1.5	6
1175	Overcome tumor relapse in CAR T cell therapy. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	2
1176	The Role of Extracellular Vesicles in Melanoma Progression. <i>Cancers</i> , 2022, 14, 3086.	1.7	15
1177	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. <i>Journal of Clinical Medicine</i> , 2022, 11, 3364.	1.0	20
1178	A Simple and Easy Evaluation Method for Urinary Extracellular Vesicles Quality. <i>Biology Bulletin</i> , 2022, 49, 142-149.	0.1	0
1179	Potentiality of Exosomal Proteins as Novel Cancer Biomarkers for Liquid Biopsy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	26
1180	Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	16
1181	Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6832.	1.8	15
1182	Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 348, 572-589.	4.8	10

#	ARTICLE	IF	CITATIONS
1183	Regulation of in vivo fate of exosomes for therapeutic applications: New frontier in nanomedicines. <i>Journal of Controlled Release</i> , 2022, 348, 483-488.	4.8	7
1184	Bioinspired nano-vaccine construction by antigen pre-degradation for boosting cancer personalized immunotherapy. <i>Biomaterials</i> , 2022, 287, 121628.	5.7	13
1185	Exosome-mediated remodeling of the tumor microenvironment: From local to distant intercellular communication. <i>Cancer Letters</i> , 2022, 543, 215796.	3.2	31
1186	Liquid Biopsies: Flowing Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 341-368.	0.8	1
1187	Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 794-813.	0.9	2
1188	Promising Role of Natural Exosomal Nanoparticles in Cancer Chemoimmunotherapy. <i>Current Drug Metabolism</i> , 2022, 23, .	0.7	1
1189	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
1190	Nonviral vector system for cancer immunogene therapy. , 2022, 1, .		2
1191	Comprehensive Pan-Cancer Analysis of TRPM8 in Tumor Metabolism and Immune Escape. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1192	The role of extracellular vesicles in animal reproduction and diseases. <i>Journal of Animal Science and Biotechnology</i> , 2022, 13, .	2.1	15
1193	Exosomal microRNAs (exoMIRs): micromolecules with macro impact in oral cancer. <i>3 Biotech</i> , 2022, 12, .	1.1	22
1194	Immune organoids: from tumor modeling to precision oncology. <i>Trends in Cancer</i> , 2022, 8, 870-880.	3.8	16
1195	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	23
1196	Analysis of scientific evidence on the effectiveness of immunomodulation in cancer: a systematic review. <i>Research, Society and Development</i> , 2022, 11, e47311922721.	0.0	0
1197	Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. <i>PLoS Pathogens</i> , 2022, 18, e1010673.	2.1	4
1198	Endothelial cells induce degradation of ECM through enhanced secretion of MMP14 carried on extracellular vesicles in venous malformation. <i>Cell and Tissue Research</i> , 2022, 389, 517-530.	1.5	1
1199	Quantificationâ€romoted Discovery of Glycosylated Exosomal PDâ€1 as a Potential Tumor Biomarker. <i>Small Methods</i> , 2022, 6, .	4.6	18
1200	Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. <i>Cancer Letters</i> , 2022, 548, 215823.	3.2	21



#	ARTICLE	IF	CITATIONS
1201	Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy. <i>Pharmaceuticals</i> , 2022, 15, 876.	1.7	6
1202	Scavenging Tumor-Derived Small Extracellular Vesicles by Functionalized 2D Materials to Inhibit Tumor Regrowth and Metastasis Following Radiotherapy. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	8
1203	Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma. <i>Oncology Reports</i> , 2022, 48, .	1.2	2
1204	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
1205	Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2023, 152, 110-122.	2.3	6
1206	Are extracellular vesicles ready for the clinical laboratory?. <i>Laboratoriums Medizin</i> , 2022, 46, 273-282.	0.1	9
1207	Engineered exosomes for studies in tumor immunology. <i>Immunological Reviews</i> , 2022, 312, 76-102.	2.8	18
1208	Liquid Biopsy in Pre-Metastatic Niche: From Molecular Mechanism to Clinical Application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1210	<sc>USP8</sc> promotes cancer progression and extracellular vesicle-mediated <sc>CD8</sc>+ T cell exhaustion by deubiquitinating the <sc>TGF</sc>- $\beta$ 2 receptor <sc>TIRI</sc>. <i>EMBO Journal</i> , 2022, 41, .	3.5	20
1211	Data driven and biophysical insights into the regulation of trafficking vesicles by extracellular matrix stiffness. <i>IScience</i> , 2022, 25, 104721.	1.9	1
1212	Lentivirus-mediated PD-L1 overexpression in bone marrow-derived dendritic cells induces immune tolerance in a rat keratoplasty model. <i>Transplant Immunology</i> , 2022, 74, 101654.	0.6	0
1213	A secretory form of Parkin-independent mitophagy contributes to the repertoire of extracellular vesicles released into the tumour interstitial fluid in vivo. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	4
1214	CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1215	Brain-derived programmed death-ligand 1 mediates immunosuppression post intracerebral hemorrhage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 2048-2057.	2.4	3
1216	Surface-engineered chlorella alleviated hypoxic tumor microenvironment for enhanced chemotherapy and immunotherapy of first-line drugs. <i>Materials Today</i> , 2022, 58, 57-70.	8.3	8
1217	Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms. <i>Pharmacological Research</i> , 2022, 183, 106364.	3.1	18
1218	Immunology and immunotherapy in breast cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 609-618.	1.4	10
1219	Exosomes in osteoarthritis: Updated insights on pathogenesis, diagnosis, and treatment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	13

#	ARTICLE	IF	CITATIONS
1220	Molecular mechanisms and clinical applications of exosomes in prostate cancer. <i>Biomarker Research</i> , 2022, 10, .	2.8	9
1221	5-Hydroxymethylcytosine profiles in plasma cell-free DNA reflect molecular characteristics of diabetic kidney disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
1222	Breast cancer cell-derived extracellular vesicles promote CD8+T cell exhaustion via TGF- $\beta$ 2 type II receptor signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	43
1223	The value of exosome-derived noncoding RNAs in colorectal cancer proliferation, metastasis, and clinical applications. <i>Clinical and Translational Oncology</i> , 2022, 24, 2305-2318.	1.2	4
1224	Selective isolation of extracellular vesicles from minimally processed human plasma as a translational strategy for liquid biopsies. <i>Biomarker Research</i> , 2022, 10, .	2.8	8
1225	Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	10
1226	Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4036.	1.7	5
1227	Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting. <i>Cancers</i> , 2022, 14, 3968.	1.7	2
1228	Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion. <i>Cancers</i> , 2022, 14, 4020.	1.7	6
1229	The roles of extracellular vesicles in the immune system. <i>Nature Reviews Immunology</i> , 2023, 23, 236-250.	10.6	228
1230	Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 817-817.	0.7	2
1231	From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
1232	The role of extracellular vesicles in cellular senescence. <i>FEBS Journal</i> , 2023, 290, 1203-1211.	2.2	8
1233	Biomarkers for response to immunotherapy in hepatobiliary malignancies. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 413-419.	0.6	12
1234	Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8599.	1.8	10
1235	The changes in peripheral blood Th17 and Treg ratios in Hashimoto's thyroiditis are accompanied by differential PD-1/PD-L1 expression. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
1236	Blockade of exosome release alters HER2 trafficking to the plasma membrane and gives a boost to Trastuzumab. <i>Clinical and Translational Oncology</i> , 2023, 25, 185-198.	1.2	4
1237	CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. <i>Science Signaling</i> , 2022, 15, .	1.6	33

#	ARTICLE	IF	CITATIONS
1238	Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	17
1239	Extracellular vesicle-mediated immunoregulation in cancer. <i>International Journal of Hematology</i> , 0, , .	0.7	3
1240	Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1. <i>Pharmaceutics</i> , 2022, 14, 1660.	2.0	17
1241	Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1. <i>Cancers</i> , 2022, 14, 4081.	1.7	8
1243	A cryostat-based frozen section method to increase the yield of extracellular vesicles extracted from different tissues. <i>BioTechniques</i> , 2022, 73, 90-98.	0.8	0
1244	Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1245	Mechanisms of extracellular vesicle-mediated immune evasion in melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1246	Commentary: High-metastatic melanoma cells promote the metastatic capability of low-metastatic melanoma cells via exosomal transfer of miR-411-5p. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1247	Neural stem cell-derived exosomes transfer miR-124-3p into cells to inhibit glioma growth by targeting FLOT2. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	16
1248	A shared, stochastic pathway mediates exosome protein budding along plasma and endosome membranes. <i>Journal of Biological Chemistry</i> , 2022, 298, 102394.	1.6	36
1249	Role of exosomes in lung cancer: A comprehensive insight from immunomodulation to theragnostic applications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188776.	3.3	13
1250	Combination of microtubule targeting agents with other antineoplastics for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188777.	3.3	12
1251	Engineered extracellular vesicles and their mimetics for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 349, 679-698.	4.8	74
1252	The evolving role of liquid biopsy in lung cancer. <i>Lung Cancer</i> , 2022, 172, 53-64.	0.9	19
1253	Simultaneous detection of cancerous exosomal miRNA-21 and PD-L1 with a sensitive dual-cycling nanoprobe. <i>Biosensors and Bioelectronics</i> , 2022, 216, 114636.	5.3	16
1254	Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1379-1389.	3.2	20
1255	Development of an exosome-related and immune microenvironment prognostic signature in colon adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
1256	Exosomal B7-4 from irradiated glioblastoma cells contributes to increase FoxP3 expression of differentiating Th1 cells and promotes tumor growth. <i>Redox Biology</i> , 2022, 56, 102454.	3.9	12

#	ARTICLE	IF	CITATIONS
1257	The distinct roles of exosomes in innate immune responses and therapeutic applications in cancer. <i>European Journal of Pharmacology</i> , 2022, 933, 175292.	1.7	21
1258	HIF-1 $\alpha$ inhibits T-2 toxin-mediated "immune evasion" process by negatively regulating PD-1/PD-L1. <i>Toxicology</i> , 2022, 480, 153324.	2.0	9
1259	Downregulation of exosomal MHC-I promotes glioma cells escaping from systemic immunosurveillance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 46, 102605.	1.7	5
1260	Role of extracellular vesicles in osteosarcoma. <i>International Journal of Medical Sciences</i> , 2022, 19, 1216-1226.	1.1	11
1261	Bioinspired Nanomaterials and Nanostructures from Nanobiology to Nanomedicine. <i>Micro/Nano Technologies</i> , 2022, , 1-31.	0.1	0
1262	NKG2D Ligands in Liquid Biopsy: The Importance of Soluble and Vesicle-Bound Proteins for Immune Modulation. <i>Critical Reviews in Immunology</i> , 2022, 42, 21-40.	1.0	3
1263	Systemic Regulation of Metastatic Disease by Extracellular Vesicles and Particles. , 2022, , 9-39.		0
1264	Exploring extracellular vesicles as mediators of clinical disease and vehicles for viral therapeutics: Insights from the COVID-19 pandemic. , 2022, 3, 172-88.		1
1265	Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1789-1827.	5.7	14
1266	Advances in liquid biopsy in neuroblastoma. <i>Fundamental Research</i> , 2022, , .	1.6	1
1267	Diagnosis of paediatric tuberculosis by optically detecting two virulence factors on extracellular vesicles in blood samples. <i>Nature Biomedical Engineering</i> , 2022, 6, 979-991.	11.6	26
1268	Upregulation of PD-L1 in Senescence and Aging. <i>Molecular and Cellular Biology</i> , 2022, 42, .	1.1	24
1269	Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment. , 2022, 39, .		6
1270	Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	63
1271	Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle. <i>Oncogenesis</i> , 2022, 11, .	2.1	59
1273	Emerging roles of extracellular vesicles in normal and malignant hematopoiesis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	5
1274	The role and application of small extracellular vesicles in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1275	Phase separation in immune regulation and immune-related diseases. <i>Journal of Molecular Medicine</i> , 2022, 100, 1427-1440.	1.7	3

#	ARTICLE	IF	CITATIONS
1276	<i>Astragalus</i> polysaccharide (APS) attenuated PD-L1-mediated immunosuppression via the miR-133a-3p/MSN axis in HCC. <i>Pharmaceutical Biology</i> , 2022, 60, 1710-1720.	1.3	6
1277	Small extracellular vesicles: from promoting pre-metastatic niche formation to therapeutic strategies in breast cancer. <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	17
1278	Cancer as an infective disease: the role of EVs in tumorigenesis. <i>Molecular Oncology</i> , 2023, 17, 390-406.	2.1	4
1279	Bone Health Management in the Continuum of Prostate Cancer Disease. <i>Cancers</i> , 2022, 14, 4305.	1.7	5
1280	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1281	Hepatitis Viruses Control Host Immune Responses by Modifying the Exosomal Biogenesis Pathway and Cargo. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10862.	1.8	1
1282	Small extracellular vesicles as a multicomponent biomarker platform in urinary tract carcinomas. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	6
1283	Recent Advances in CRISPR/Cas-Based Biosensors for Protein Detection. <i>Bioengineering</i> , 2022, 9, 512.	1.6	10
1284	Isolation and analysis of tumor-derived extracellular vesicles from head and neck squamous cell carcinoma plasma by galectin-based glycan recognition particles. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	10
1285	An immunogold single extracellular vesicular RNA and protein (Au-SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	16
1286	Extracellular vesicles as central regulators of blood vessel function in cancer. <i>Science Signaling</i> , 2022, 15, .	1.6	6
1287	High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study. <i>Cancers</i> , 2022, 14, 4748.	1.7	3
1288	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1289	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1290	Interferon- $\beta$ induces immunosuppression in salivary adenoid cystic carcinoma by regulating programmed death ligand 1 secretion. <i>International Journal of Oral Science</i> , 2022, 14, .	3.6	9
1291	Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics**. <i>ChemBioChem</i> , 2022, 23, .	1.3	4
1292	The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer. <i>Experimental and Molecular Medicine</i> , 0, , .	3.2	18
1293	The role of soluble CD80 in patients with soft tissue tumors. <i>Journal of Orthopaedic Surgery and Research</i> , 2022, 17, .	0.9	2

#	ARTICLE	IF	CITATIONS
1294	Anti-tumour potential of PD-L1 post-translational modifications. <i>Immunology</i> , 2022, 167, 471-481.	2.0	10
1295	Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer. <i>Tissue and Cell</i> , 2022, 79, 101941.	1.0	5
1296	Extracellular vesicle-based checkpoint regulation and immune state in cancer. , 2022, 39, .		10
1297	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
1298	Enterovirus 71 non-structural protein 3A hijacks vacuolar protein sorting 25 to boost exosome biogenesis to facilitate viral replication. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	8
1300	Cathepsin L-containing exosomes from $\alpha$ -synuclein-activated microglia induce neurotoxicity through the P2X7 receptor. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	9
1301	From simplicity to complexity in current melanoma models. <i>Experimental Dermatology</i> , 2022, 31, 1818-1836.	1.4	3
1302	Exosomal Communication Between the Tumor Microenvironment and Innate Immunity and Its Therapeutic Application. <i>Immune Network</i> , 2022, 22, .	1.6	7
1303	Immunomodulatory Effect and Bone Homeostasis Regulation in Osteoblasts Differentiated from hADMSCs via the PD-1/PD-L1 Axis. <i>Cells</i> , 2022, 11, 3152.	1.8	0
1304	Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy. <i>Cancers</i> , 2022, 14, 5121.	1.7	4
1306	Molecular Docking and Intracellular Translocation of Extracellular Vesicles for Efficient Drug Delivery. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12971.	1.8	1
1307	Understanding the extracellular vesicle surface for clinical molecular biology. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	22
1308	Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice. <i>International Journal of Pharmaceutics</i> , 2022, 629, 122352.	2.6	5
1309	The function and clinical implication of circular RNAs in lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1310	Exosome-mediated cell-cell communication within pancreatic cancer tumor microenvironment: a narrative review. <i>Journal of Pancreatology</i> , 0, Publish Ahead of Print, .	0.3	0
1311	New frontiers of oral sciences: Focus on the source and biomedical application of extracellular vesicles. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1312	CD11c+ myeloid cell exosomes reduce intestinal inflammation during colitis. <i>JCI Insight</i> , 2022, 7, .	2.3	4
1313	Fluid nanoporous microinterface enables multiscale-enhanced affinity interaction for tumor-derived extracellular vesicle detection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	18

#	ARTICLE	IF	CITATIONS
1314	TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems. <i>Cancers</i> , 2022, 14, 5125.	1.7	13
1315	Less is More: Preorganization Leads to Better Tumor Retention and Therapeutic Efficacy. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	5
1316	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. <i>Biomedicines</i> , 2022, 10, 2511.	1.4	10
1317	Effects of exosomes on tumor immunomodulation and their potential clinical applications (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	6
1318	Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications. <i>Advanced Science</i> , 2022, 9, .	5.6	28
1319	Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1. , 2022, 19, 1290-1301.		13
1321	Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. <i>Cells</i> , 2022, 11, 3365.	1.8	4
1322	Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1323	Single-Step and Highly Sensitive Imaging of Exosomal PD-L1 through Aptamer-Activated Cascade Primer Exchange Reaction-Generated Branched DNA Nanostructures. <i>ACS Sensors</i> , 2022, 7, 3571-3579.	4.0	13
1324	IGF2BP2 promotes cancer progression by degrading the RNA transcript encoding a v-ATPase subunit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
1325	Effect of <i>Lacticaseibacillus rhamnosus</i> and <i>Lactiplantibacillus plantarum</i> isolated from food and human origin on reduction of IgE-dependent hypersensitivity in Balb/c mice. <i>Immunobiology</i> , 2022, 227, 152292.	0.8	2
1326	The cancer cell-derived extracellular vesicle glycode in immunoevasion. <i>Trends in Immunology</i> , 2022, 43, 864-867.	2.9	14
1327	Small Extracellular Vesicles Loaded with Immunosuppressive miRNAs Leads to an Inhibition of Dendritic Cell Maturation. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, .	1.0	3
1328	The role and underlying mechanisms of tumour-derived exosomes in lung cancer metastasis. <i>Current Opinion in Oncology</i> , 2023, 35, 46-53.	1.1	2
1329	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1572.	0.8	5
1330	Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. <i>Molecular Cancer</i> , 2022, 21, .	7.9	109
1331	VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. <i>Life Sciences</i> , 2022, 310, 121083.	2.0	19
1332	The emerging roles of exosome-derived noncoding RNAs in the tumor immune microenvironment and their future applications. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113863.	2.5	5

#	ARTICLE	IF	CITATIONS
1333	An integrated magneto-fluorescent nanosensor for rapid and sensitive detection of tumor-derived exosomes. <i>Sensors and Actuators B: Chemical</i> , 2023, 374, 132792.	4.0	11
1334	The second near-infrared window quantum dot-based fluorescence anisotropy probes for separation-free, sensitive and rapid detection of small extracellular vesicle PD-L1 in plasma samples. <i>Sensors and Actuators B: Chemical</i> , 2023, 376, 132962.	4.0	3
1335	Phospholipid-Membrane-Based Nanovesicles Acting as Vaccines for Tumor Immunotherapy: Classification, Mechanisms and Applications. <i>Pharmaceutics</i> , 2022, 14, 2446.	2.0	6
1336	Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma. <i>Clinical Cancer Research</i> , 2023, 29, 659-666.	3.2	6
1337	Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 5618.	1.7	2
1338	Monocrystalline Labeling Enables Stable Plasmonic Enhancement for Isolation-Free Extracellular Vesicle Analysis. <i>Small</i> , 2023, 19, .	5.2	4
1339	Nanomaterials: small particles show huge possibilities for cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	14
1341	Large tumour-derived extracellular vesicles as prognostic indicators of metastatic cancer patient survival. <i>British Journal of Cancer</i> , 2023, 128, 471-473.	2.9	1
1342	Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach. <i>Cancers</i> , 2022, 14, 5605.	1.7	4
1343	Extracellular Vesicles as an Endocrine Mechanism Connecting Distant Cells. <i>Molecules and Cells</i> , 2022, 45, 771-780.	1.0	5
1344	The application of exosomes in the treatment of triple-negative breast cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
1345	Establishment and characterization of adult human gastric epithelial progenitor-like cell lines. <i>Cell Proliferation</i> , 0, , .	2.4	0
1346	The role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity. <i>Military Medical Research</i> , 2022, 9, .	1.9	22
1347	Exosomes in HBV infection. <i>Clinica Chimica Acta</i> , 2023, 538, 65-69.	0.5	5
1348	Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis. <i>Bosnian Journal of Basic Medical Sciences</i> , 2023, 23, .	0.6	5
1349	Importance and implications of exosomes in nephrology and urology. <i>Pflugers Archiv European Journal of Physiology</i> , 0, , .	1.3	1
1350	<sc>KCNQ1OT1</sc> sponges <sc>miR</sc>â€³4a to promote malignant progression of malignant melanoma via upregulation of the <sc>STAT3</sc>/<sc>PDâ€¹1</sc> axis. <i>Environmental Toxicology</i> , 2023, 38, 368-380.	2.1	6
1351	Exosomes in Genitourinary Cancers: Emerging Mediators of Drug Resistance and Promising Biomarkers. <i>International Journal of Biological Sciences</i> , 2023, 19, 167-182.	2.6	3



#	ARTICLE	IF	CITATIONS
1352	Exosomes-mediated tumor metastasis through reshaping tumor microenvironment and distant niche. <i>Journal of Controlled Release</i> , 2023, 353, 327-336.	4.8	15
1353	Metabolites as extracellular vesicle cargo in health, cancer, pleural effusion, and cardiovascular diseases: An emerging field of study to diagnostic and therapeutic purposes. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114046.	2.5	12
1354	Exosomes in sarcoma: Prospects for clinical applications. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103895.	2.0	0
1355	Selective enrichment and detection of PD-L1 positive extracellular vesicles derived from human plasma and patient derived tumor cells. <i>Sensors and Actuators B: Chemical</i> , 2023, 377, 133086.	4.0	0
1356	Predictive and On-Treatment Monitoring Role of Circulating Biomarkers in Immuno-oncology. , 2022, , 1-20.		1
1357	High Throughput Isolation and Data Independent Acquisition Mass Spectrometry (DIA-MS) of Urinary Extracellular Vesicles to Improve Prostate Cancer Diagnosis. <i>Molecules</i> , 2022, 27, 8155.	1.7	3
1358	Predictive biomarkers of colon cancer immunotherapy: Present and future. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	30
1359	Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	17
1361	Organism-Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy. <i>Advanced Science</i> , 2023, 10, .	5.6	5
1362	Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment. <i>Journal of Clinical Medicine</i> , 2022, 11, 6892.	1.0	8
1363	Quantitative proteomic analysis of exosomes from umbilical cord mesenchymal stem cells and rat bone marrow stem cells. <i>Proteomics</i> , 2023, 23, .	1.3	2
1364	Tumor-Derived Membrane Vesicles from the IL-2 Overexpression Melanoma Cells Affect on the Expression of Surface Markers of Human Peripheral Blood Mononuclear Cells In Vitro. <i>BioNanoScience</i> , 0, , .	1.5	0
1365	Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. <i>Medical Alphabet</i> , 2022, , 35-40.	0.0	2
1366	Divergent roles of PD-L1 in immune regulation during ischemia-reperfusion injury. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1367	Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1833-1843.	3.2	17
1368	Mechanisms of colorectal liver metastasis development. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	7
1369	Aptamer-Assisted Traceless Isolation of PD-L1-Positive Small Extracellular Vesicles for Dissecting Their Subpopulation Signature and Function. <i>Analytical Chemistry</i> , 0, , .	3.2	3
1370	Prediction of tissue-of-origin of early stage cancers using serum miRNomes. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	1.4	10

#	ARTICLE	IF	CITATIONS
1371	Tumor-Derived Small Extracellular Vesicles Involved in Breast Cancer Progression and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15236.	1.8	2
1372	Manipulation of PD-L1 Endosomal Trafficking Promotes Anticancer Immunity. <i>Advanced Science</i> , 2023, 10, .	5.6	6
1373	Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy. <i>Life</i> , 2022, 12, 2104.	1.1	5
1374	Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. , 2023, 241, 108332.		4
1375	Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model. <i>Cancer Immunology Research</i> , 2023, 11, 217-227.	1.6	4
1376	Introduction on Personalized Immune-Oncology. , 2023, , 1-25.		0
1377	Exosomes Derived from Immune Cells: The New Role of Tumor Immune Microenvironment and Tumor Therapy. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 6527-6550.	3.3	10
1378	Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics. <i>Cancers</i> , 2023, 15, 82.	1.7	5
1379	Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	7
1380	Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
1381	HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti-PD-1 Treatment Efficacy. <i>Cancer Immunology Research</i> , 2023, 11, 228-240.	1.6	5
1382	CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals. <i>ELife</i> , 0, 11, .	2.8	11
1383	Extracellular vesicles as novel therapeutic targets and diagnosis markers. , 2022, 1, 100017.		1
1384	Single-Particle Optical Imaging for Ultrasensitive Bioanalysis. <i>Biosensors</i> , 2022, 12, 1105.	2.3	1
1385	Assessment of PD-L1 mRNA expression in gastrointestinal tumors and the response to immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1386	Immunogenic Nanovesicle-Tandem-Augmented Chemoimmunotherapy via Efficient Cancer-Homing Delivery and Optimized Ordinal-Interval Regime. <i>Advanced Science</i> , 2023, 10, .	5.6	10
1387	Assembly of Nanocatalyst As a Noninvasive Tool for Breast Cancer Diagnosis and Immunotherapy Surveillance Designed by Visually Tracking Tumor-Derived Exosomal PD-L1. , 0, , 282-290.		0
1388	Fluidic Membrane Accelerating the Kinetics of Photoactivatable Hybridization Chain Reaction for Accurate Imaging of Tumor-Derived Exosomes. <i>Analytical Chemistry</i> , 2022, 94, 17645-17652.	3.2	5

#	ARTICLE	IF	CITATIONS
1389	Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	13
1390	Immunosuppressive Extracellular Vesicles in CLL. <i>Blood Cancer Discovery</i> , 2023, 4, 5-7.	2.6	1
1391	Suppression of exosomal hsa_circ_0001005 eliminates the Vemurafenib resistance of melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5921-5936.	1.2	2
1392	Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
1393	Thiolate DNAzymes on Gold Nanoparticles for Isothermal Amplification and Detection of Mesothelioma-derived Exosomal PD-L1 mRNA. <i>Analytical Chemistry</i> , 2023, 95, 3228-3237.	3.2	2
1394	Shaping Up the Tumor Microenvironment: Extracellular Vesicles as Important Intermediaries in Building a Tumor-Supportive Cellular Network. <i>Cancers</i> , 2023, 15, 501.	1.7	1
1395	CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
1396	Extracellular Vesicles-Based Cell-Cell Communication in Melanoma: New Perspectives in Diagnostics and Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 965.	1.8	2
1397	Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	27
1398	Immunosuppressive functions of melanoma cell-derived exosomes in plasma of melanoma patients. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
1399	Extracellular Vesicles: New Classification and Tumor Immunosuppression. <i>Biology</i> , 2023, 12, 110.	1.3	21
1400	Extracellular Vesicles Are Important Mediators That Regulate Tumor Lymph Node Metastasis via the Immune System. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1362.	1.8	3
1401	Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1294.	1.8	6
1402	Bioinspired Nanomaterials and Nanostructures from Nanobiology to Nanomedicine. <i>Micro/Nano Technologies</i> , 2023, , 19-48.	0.1	1
1403	Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	8
1404	Nanomedicines in oral cancer: inspiration comes from extracellular vesicles and biomimetic nanoparticles. <i>Nanomedicine</i> , 2022, 17, 1761-1778.	1.7	6
1405	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1406	Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	1

#	ARTICLE	IF	CITATIONS
1407	Anti-angiogenic effect of exo-LncRNA TUG1 in myocardial infarction and modulation by remote ischemic conditioning. <i>Basic Research in Cardiology</i> , 2023, 118, .	2.5	7
1408	Identification of a cuproptosis-related lncRNA prognostic signature in lung adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2023, 25, 1617-1628.	1.2	1
1409	Advanced technologies for molecular diagnosis of cancer: State of pre-clinical tumor-derived exosome liquid biopsies. <i>Materials Today Bio</i> , 2023, 18, 100538.	2.6	13
1410	Rab11a-Regulated Exosomes Inhibit Bacterial Infection through the Activation of Antilipopolysaccharide Factors in Crustaceans. <i>Journal of Immunology</i> , 2022, 209, 710-722.	0.4	3
1411	Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms. <i>Trends in Cancer</i> , 2023, 9, 198-211.	3.8	6
1412	Role of Extracellular Vesicles in Cancer Pathogenesis. , 2023, , 1-29.		0
1413	Trace Analysis of Multiple Tumor Exosomal PD-L1 Based on SERS Immunoassay Platform. , 2023, 2, .		2
1414	Long non-coding RNAs (lncRNAs) in hepatocellular carcinoma progression: Biological functions and new therapeutic targets. <i>Progress in Biophysics and Molecular Biology</i> , 2023, 177, 207-228.	1.4	2
1415	Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1406-1406.	0.7	13
1416	Cancer Exosomes: An Overview and the Applications of Flow. <i>Fluids</i> , 2023, 8, 7.	0.8	0
1417	Mitochondrial DNA and inflammatory proteins are higher in extracellular vesicles from frail individuals. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	4
1418	Passive Membrane Permeability of Sizable Acyclic $\beta$ -Hairpin Peptides. <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 278-284.	1.3	1
1419	Effects of Exosomes on Tumor Bioregulation and Diagnosis. <i>ACS Omega</i> , 2023, 8, 5157-5168.	1.6	4
1420	Tumor immunology. , 2023, , 245-452.		0
1421	Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma. <i>Cancers</i> , 2023, 15, 602.	1.7	10
1422	The Rise of Extracellular Vesicles as New Age Biomarkers in Cancer Diagnosis: Promises and Pitfalls. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211492.	0.8	6
1423	Electroformed Inverse Opal Nanostructures for Surface Marker-Specific Isolation of Extracellular Vesicles Directly from Complex Media. <i>Advanced Materials Technologies</i> , 2023, 8, .	3.0	2
1424	Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2

#	ARTICLE	IF	CITATIONS
1425	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
1426	Which technology performs better? From sample volume to extraction and molecular profiling. , 2023, , 119-202.		0
1427	Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship. <i>Microorganisms</i> , 2023, 11, 267.	1.6	4
1428	Liquid biopsy and immunotherapy: is all that glitter gold?. , 2023, , 83-117.		0
1429	Cancer stem cell-derived extracellular vesicles preferentially target MHC-IIâ€‘macrophages and PD1+ T cells in the tumor microenvironment. <i>PLoS ONE</i> , 2023, 18, e0279400.	1.1	6
1430	Optimization of cancer immunotherapy on the basis of programmed death ligandâ€‘1 distribution and function. <i>British Journal of Pharmacology</i> , 2024, 181, 257-272.	2.7	4
1431	Stiff matrix induces exosome secretion to promote tumour growth. <i>Nature Cell Biology</i> , 2023, 25, 415-424.	4.6	37
1432	Extracellular vesicles: A dive into their role in the tumor microenvironment and cancer progression. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	5
1433	Biomarker discovery and applicationâ€‘An opportunity to resolve the challenge of liver cancer diagnosis and treatment. <i>Pharmacological Research</i> , 2023, 189, 106674.	3.1	5
1434	Tumor-Derived PD-L1<sup>+</sup> Exosomes with Natural Inflammation Tropism for Psoriasis-Targeted Treatment. <i>Bioconjugate Chemistry</i> , 0, , .	1.8	2
1435	Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives. <i>Pharmaceutics</i> , 2023, 15, 1143.	2.0	13
1436	Colorectal cancer-derived extracellular vesicles containing HSP70 enhance macrophage phagocytosis by up-regulating MARCO expression. <i>Experimental Cell Research</i> , 2023, 426, 113565.	1.2	3
1437	Propranolol reduces IFN-Î³ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer. <i>Brain, Behavior, and Immunity</i> , 2023, 110, 1-12.	2.0	6
1438	The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia. <i>Biochemical Pharmacology</i> , 2023, 212, 115539.	2.0	5
1439	Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy. <i>Bioactive Materials</i> , 2023, 27, 168-180.	8.6	5
1440	A Fluid Multivalent Magnetic Interface for Highâ€‘Performance Isolation and Proteomic Profiling of Tumorâ€‘Derived Extracellular Vesicles. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	0
1441	Rapid and efficient fluorescent aptasensor for PD-L1 positive extracellular vesicles isolation and analysis: EV-ANCHOR. <i>Chemical Engineering Journal</i> , 2023, 465, 142811.	6.6	2
1442	RNA profile of immunoâ€‘magnetically enriched lung cancer associated exosomes isolated from clinical samples. <i>Cancer Genetics</i> , 2023, 274-275, 59-71.	0.2	0

#	ARTICLE	IF	CITATIONS
1443	Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. <i>International Immunopharmacology</i> , 2023, 118, 110092.	1.7	5
1444	Nutrient-sensing nanoprotoplast augments tumor accumulation and immune response with short-term starvation. <i>Nano Today</i> , 2023, 49, 101762.	6.2	0
1445	The Roles of Exosomes in the Diagnose, Development and Therapeutic Resistance of Oral Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1968.	1.8	6
1446	Extracellular vesicles as a liquid biopsy for melanoma: Are we there yet?. <i>Seminars in Cancer Biology</i> , 2023, 89, 92-98.	4.3	2
1447	Immunology and immunotherapy of cholangiocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 349-365.	8.2	28
1448	Extracellular vesicles secreted by triple-negative breast cancer stem cells trigger premetastatic niche remodeling and metastatic growth in the lungs. <i>International Journal of Cancer</i> , 2023, 152, 2153-2165.	2.3	8
1449	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. <i>Biology</i> , 2023, 12, 218.	1.3	27
1450	A Versatile Design-Enabled Analysis of Circulating Extracellular Vesicles in Disease Diagnosis. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	3
1451	Tumour-derived exosomes and their emerging roles in leukaemia (Review). <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	1
1453	Tumour-derived small extracellular vesicles contribute to the tumour progression through reshaping the systemic immune macroenvironment. <i>British Journal of Cancer</i> , 2023, 128, 1249-1266.	2.9	2
1454	Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy. <i>Cancers</i> , 2023, 15, 1074.	1.7	2
1455	Challenges and opportunities of CAR T-cell therapies for CLL. <i>Seminars in Hematology</i> , 2023, 60, 25-33.	1.8	3
1456	Context-specific regulation of extracellular vesicle biogenesis and cargo selection. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 454-476.	16.1	112
1457	Roles of cancer-associated fibroblasts (CAFs) in anti-PD-1/PD-L1 immunotherapy for solid cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	36
1458	Evaluating tumor cell- and T cell-derived extracellular vesicles as potential biomarkers of cancer and immune cell competence. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 109-122.	1.5	2
1459	Immunological priming of mesenchymal stromal/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease via engagement of PD-1 ligands. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
1460	Production and Utility of Extracellular Vesicles with 3D Culture Methods. <i>Pharmaceutics</i> , 2023, 15, 663.	2.0	8
1461	GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer metastasis. <i>Developmental Cell</i> , 2023, 58, 320-334.e8.	3.1	20

#	ARTICLE	IF	CITATIONS
1462	Accurate and rapid quantification of PD-L1 positive exosomes by a triple-helix molecular probe. <i>Analytica Chimica Acta</i> , 2023, 1251, 340984.	2.6	3
1463	Curcuma Rhizoma Exosomes-like nanoparticles loaded Astragalus components improve the absorption and enhance anti-tumor effect. <i>Journal of Drug Delivery Science and Technology</i> , 2023, 81, 104274.	1.4	8
1464	Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4014.	1.8	5
1465	Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading. <i>Molecular Therapy</i> , 2023, 31, 1231-1250.	3.7	32
1466	Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors. <i>Cancers</i> , 2023, 15, 1307.	1.7	18
1467	Liquid Biopsies in Lung Cancer. <i>Cancers</i> , 2023, 15, 1430.	1.7	7
1468	Shaping of the Clinical Landscape of Immunotherapy by PD-L1 Expression in Breast Cancer. , 2023, , 1-20.		0
1469	Bioengineered MSC-derived exosomes in skin wound repair and regeneration. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	15
1470	Application of plasma membrane proteomics to identify cancer biomarkers. , 2023, , 287-317.		0
1471	The diagnostic and therapeutic prospects of exosomes in ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2023, 130, 999-1006.	1.1	2
1472	ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. <i>NAR Cancer</i> , 2023, 5, .	1.6	0
1473	Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
1474	Recent progress in aptamer-based microfluidics for the detection of circulating tumor cells and extracellular vesicles. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 340-354.	2.4	6
1475	Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cells</i> , 2023, 12, 832.	1.8	10
1476	PD-1/PD-L1 Signaling Pathway and Tumor Immune Escape. <i>Journal of Biosciences and Medicines</i> , 2023, 11, 9-16.	0.1	0
1477	Intercellular hif1 $\alpha$ reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	3
1478	Role of regulation of PD-1 and PD-L1 expression in sepsis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1479	Exosomal PD-L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 2023, 49, .	1.2	1

#	ARTICLE	IF	CITATIONS
1480	The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. <i>Cancer Cell</i> , 2023, 41, 374-403.	7.7	298
1481	cRGD-modified nanoparticles of multi-bioactive agent conjugate with pH-sensitive linkers and PD-L1 antagonist for integrative collaborative treatment of breast cancer. <i>Nanoscale Horizons</i> , 2023, 8, 870-886.	4.1	3
1482	Engineered exosomes from different sources for cancer-targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	51
1483	Hypoxic nasopharyngeal carcinoma-derived exosomal miR-455 increases vascular permeability by targeting ZO-1 to promote metastasis. <i>Molecular Carcinogenesis</i> , 2023, 62, 803-819.	1.3	3
1484	Exosomes, microvesicles, and other extracellular vesicles—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1523, 24-37.	1.8	4
1485	Soluble PD-L1 reflects cachexia status in patients with gastric cancer and is an independent prognostic marker for relapse-free survival after radical surgery. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	1
1486	Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19.		0
1487	Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy. <i>Nature Materials</i> , 2023, 22, 656-665.	13.3	12
1488	A Fluid Multivalent Magnetic Interface for High-Performance Isolation and Proteomic Profiling of Tumor-Derived Extracellular Vesicles. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	10
1489	The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy. <i>Genes and Diseases</i> , 2024, 11, 321-334.	1.5	5
1490	The impact of hypoxia on extracellular vesicle secretome profile of cancer. , 2023, 40, .		4
1492	Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active Smoking. <i>Current Issues in Molecular Biology</i> , 2023, 45, 2781-2797.	1.0	2
1493	Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1494	Programmable DNA Circuit-Facilitated Determination of Circulating Extracellular Vesicle PD-L1 for Lung Cancer Diagnosis and Immunotherapy Response Prediction. <i>ACS Applied Materials &amp; Interfaces</i> , 2023, 15, 17696-17704.	4.0	1
1495	Exosome-disrupting peptides for cancer immunotherapy. <i>Nature Materials</i> , 2023, 22, 530-531.	13.3	1
1496	Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	11
1497	Immunotherapy Approaches for Breast Cancer Patients in 2023. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2023, 13, a041332.	2.9	9
1498	Tumour-derived extracellular vesicle based vaccines for melanoma treatment. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1520-1542.	3.0	3



#	ARTICLE	IF	CITATIONS
1499	Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy. <i>Analytical Chemistry</i> , 2023, 95, 6854-6862.	3.2	8
1500	Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy. <i>Biomedicines</i> , 2023, 11, 1130.	1.4	3
1501	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. <i>Advances in Anatomic Pathology</i> , 2023, 30, 174-194.	2.4	0
1502	Phosphatidylserine-positive extracellular vesicles boost effector CD8 <sup>+</sup> T cell responses during viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	2
1503	Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. <i>Journal of Cancer</i> , 2023, 14, 850-873.	1.2	5
1504	Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy. , 2023, 150, 213425.		2
1505	The role of extracellular vesicles in cancer. <i>Cell</i> , 2023, 186, 1610-1626.	13.5	76
1506	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. <i>Cancers</i> , 2023, 15, 2273.	1.7	2
1507	Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. <i>Talanta</i> , 2023, 259, 124553.	2.9	1
1508	Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. , 2023, 20, 694-713.		8
1509	Glucose metabolism of TAMs in tumor chemoresistance and metastasis. <i>Trends in Cell Biology</i> , 2023, 33, 967-978.	3.6	7
1511	Dissecting order amidst chaos of programmed cell deaths: construction of a diagnostic model for KIRC using transcriptomic information in blood-derived exosomes and single-cell multi-omics data in tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1513	Small and Large Extracellular Vesicles Derived from Pleural Mesothelioma Cell Lines Offer Biomarker Potential. <i>Cancers</i> , 2023, 15, 2364.	1.7	0
1514	Leveraging Exosomes as the Next-Generation Bio-Shuttles: The Next Biggest Approach against Th17 Cell Catastrophe. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7647.	1.8	2
1515	Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1531	Synergy and Coordination Between Biomimetic Nanoparticles and Biological Cells/Tissues/Organs/Systems: Applications in Nanomedicine and Prospect. , 2024, 2, 1-33.		5
1556	Editorial: The functions of extracellular vesicles in melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	0
1557	Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer. , 2023, , 1-21.		0

#	ARTICLE	IF	CITATIONS
1570	Recent progress in exosome research: isolation, characterization and clinical applications. <i>Cancer Gene Therapy</i> , 2023, 30, 1051-1065.	2.2	11
1574	Potential functions and therapeutic implications of glioma-resident mesenchymal stem cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 853-866.	2.4	2
1582	Latest advances and perspectives of liquid biopsy for cancer diagnostics driven by microfluidic on-chip assays. <i>Lab on A Chip</i> , 2023, 23, 2922-2941.	3.1	7
1601	A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy. <i>Nanoscale</i> , 2023, 15, 11813-11833.	2.8	6
1605	The Detection of Exosomal PD-L1 in Peripheral Blood. <i>Methods in Molecular Biology</i> , 2023, , 195-212.	0.4	1
1631	Recent progress in quantitative technologies for the analysis of cancer-related exosome proteins. <i>Analyst, The</i> , 2023, 148, 4954-4966.	1.7	0
1642	Green Nanotechnology Approaches in Vaccinology: Advantages and Disadvantages in Biomedical Sciences. , 2023, , 281-299.		0
1645	Exploiting Exosomes for Cancer Diagnosis and Treatment. <i>Current Cancer Research</i> , 2023, , 43-59.	0.2	0
1647	Theranostic signature of tumor-derived exosomes in cancer. , 2023, 40, .		12
1654	Diagnostic liquid biopsy biomarkers in renal cell cancer. <i>Nature Reviews Urology</i> , 2024, 21, 133-157.	1.9	0
1699	Î³Î´ T cells: origin and fate, subsets, diseases and immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	7
1709	Local Onco-Sphere: Tumorâ€™Secretome Interaction. , 2023, , 101-124.		0
1716	Systemic Onco-sphere: Host Adaptive Immune System. , 2023, , 443-468.		0
1750	An overview of current development and barriers on liquid biopsy in patients with early-stage non-small-cell Lung cancer. , 2023, 2, .		0
1777	Stratification of metastatic melanoma patients based on mutational signatures. , 2023, , .		0
1787	WNT/Î²-catenin regulatory roles on PD-(L)1 and immunotherapy responses. <i>Clinical and Experimental Medicine</i> , 2024, 24, .	1.9	0
1791	Roles of exosomes in immunotherapy for solid cancers. <i>Cell Death and Disease</i> , 2024, 15, .	2.7	0
1800	Immune Checkpoint Molecules and Maternalâ€™Fetal Immunity. <i>Current Obstetrics and Gynecology Reports</i> , 2024, 13, 37-45.	0.3	0

#	ARTICLE	IF	CITATIONS
1830	Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer. , 2024, , 331-351.		0